Original Article

Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension

Adel Giaid, Masashi Yanagisawa, David Langleben, Rene P. Michel, Robert Levy, Hani Shennib, Sadao Kimura, Tomoh Masaki, William P. Duguid, and Duncan J. Stewart

N Engl J Med 1993; 328:1732-1739June 17, 1993

Abstract

Background

Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension.

Full Text of Background...

Methods

We studied the distribution of endothelin-1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3.

Full Text of Methods...

Results

In the controls, endothelin-1-like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1-like immunoreactivity. There was a strong correlation between the intensity of endothelin-1-like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension.

Full Text of Results...

Conclusions

Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 1Endothelin-1-Like Immunoreactivity in Normal Lung Tissue and Lung Tissue from Patients with Plexogenic Pulmonary Arteriopathy (Group 1) and Secondary Pulmonary Hypertension (Group 2).

Figure 2Mean (±SE) Level of Endothelin-1-Like Immunoreactivity in Vascular Endothelium of Lung Tissue from Two Groups of Controls (Panel A) and Two Groups of Patients with Pulmonary Hypertension (Panel B).

Article Activity

454 articles have cited this article

Article

Pulmonary hypertension is often a progressive condition, characterized by a relentless increase in pulmonary vascular resistance that ultimately leads to right-heart failure and death. Although the initiating factors may differ widely in patients with primary and various secondary causes of pulmonary hypertension, there may be common pathways of progression that reflect the limited range of vascular response to injury. Common to many forms of pulmonary hypertension is the proliferation of smooth-muscle cells in the vascular media and frequently the intima,1 triggered and perpetuated by as yet unknown mechanisms. The resulting intimal and medial thickening may reduce the caliber of resistance vessels and occlude small vascular channels. Furthermore, vasoconstriction may also contribute to inappropriate increases in pulmonary vascular resistance in many patients with pulmonary hypertension2.

Recently, it has been recognized that the vascular endothelium plays a crucial part in local regulation of the function of smooth-muscle cells3,4. Under physiologic conditions, the endothelium produces a variety of vasodilator mediators, which maintain an appropriate level of vascular tone and prevent the proliferation of smooth-muscle cells5,6. Under pathologic conditions, however, the endothelium can be activated to secrete factors that produce profound vasoconstriction. The most potent of these is the 21-residue peptide endothelin-1,7 which is also a mitogen for smooth muscle8-10 and other types of cells in vitro11-13. At present, it is not known whether the functional and morphologic abnormalities of small and medium-sized pulmonary arteries in patients with pulmonary hypertension are associated with an increase in the local expression and production of this potent vasoconstrictor and mitogenic peptide.

Our previous studies have demonstrated low levels of expression of endothelin-1 in the normal adult as compared with fetal lung tissue14. Indeed, the normal lung may function to clear endothelin-1 from the circulation,15 a concept supported by studies examining the gradient of plasma levels across the lung16. However, we have also shown that in patients with pulmonary hypertension -- particularly primary pulmonary hypertension -- there may be a net production and release of endothelin-1 into the pulmonary circulation16. In this report, we provide evidence of increased vascular expression of endothelin-1 in the lungs of patients with pulmonary hypertension, evidence consistent with a contributing role for endothelin-1 in the vascular manifestations of this disorder.

Methods

Study Design

The study protocol was approved by the institutional research and ethics committees of Montreal General Hospital and Royal Victoria Hospital, Montreal. Lung samples were obtained after surgical resection or at autopsy ( ≤ 10 hours post mortem). Specimens were obtained from 28 patients with a clinical diagnosis of pulmonary hypertension17. The patients were divided into two groups on the basis of clinical and histopathological characteristics. Group 1 consisted of 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6),18 of whom 7 had a clinical diagnosis of primary pulmonary hypertension according to the criteria of the National Heart, Lung, and Blood Institute19 (Table 1Table 1Characteristics of the Patients with Plexogenic Pulmonary Arteriopathy.). Group 2 consisted of 17 patients with secondary causes of pulmonary hypertension and no more than grade 3 pulmonary arteriopathy18 (Table 2Table 2Characteristics of the Patients with Secondary Pulmonary Hypertension.). The patients with secondary pulmonary hypertension were older than those with plexogenic pulmonary arteriopathy and had significantly lower forced expiratory volumes, diffusing capacities for carbon monoxide, and hemoglobin levels. However, there were no significant differences in pulmonary arterial pressure and vascular resistance between the two groups. Control specimens were obtained from 5 patients (3 men and 2 women, 19 to 67 years old [mean, 50]) with pulmonary diseases other than idiopathic pulmonary fibrosis or hypertension (e.g., interstitial pneumonitis) and from the unused normal lungs of 10 organ donors (6 female and 4 male donors, 17 to 46 years old [mean, 30]). Tissues were fixed in 10 percent buffered formalin or Bouin's solution and embedded in paraffin for routine pathological examination and immunocytochemical analysis. The method of fixation did not affect the intensity of immunostaining in five specimens that were prepared by both methods. For the localization of endothelin-1 messenger RNA (mRNA), tissues were either snap-frozen in liquid nitrogen or fixed in 4 percent paraformaldehyde in phosphate-buffered saline (0.1 mol of sodium phosphate and 0.15 mol of sodium chloride per liter, pH 7.2) and washed in phosphate-buffered saline containing 15 percent sucrose and 0.01 percent sodium azide at 4 °C.

Immunocytochemical Analysis

Two polyclonal antiserums against human endothelin-1 were used: one against the C-terminal of endothelin-1 and the other against the C-terminal fragment of big endothelin-1 (big endothelin-1_22-38). The two endothelin antiserums were raised as previously described20. A commercial antiserum against human endothelin-1 (Peninsula Laboratories, Belmont, Calif.) was also used. In addition, antiserum to von Willebrand factor (factor VIII-related antigen) (Dako, Santa Barbara, Calif.) was used as an endothelial-cell marker. The avidin-biotin-peroxidase complex method21 was used as previously described14. Negative controls were prepared with the specific antiserum absorbed with the cross-reactive endothelins or with nonimmune serum instead of primary antiserum, or by omitting steps in the avidin-biotin-peroxidase procedure.

Three sections were stained with each antiserum and graded semiquantitatively, as previously described22. The light-microscopical sections were examined for the localization of endothelin-1-like immunoreactivity, particularly in vascular endothelium and airway epithelium. Staining intensity was graded semiquantitatively from 0 to 4, with 0 representing the absence of any staining and 4 the maximal intensity, corresponding to the intensity of staining with factor VIII. The grading was performed by two of the investigators, without prior knowledge of diagnostic category or clinical information. Additional sections from each specimen were stained with hematoxylin and eosin for pathological grading according to the system of Heath and Edwards18.

In Situ Hybridization

Ten-micrometer cryostat sections from paraformaldehyde-fixed tissues were rehydrated in phosphate-buffered saline, rendered permeable with proteinase K, and immersed in 4 percent paraformaldehyde for five minutes to stop the reaction. After three washes in phosphate-buffered saline, sections were immersed in a solution of triethanolamine (0.1 mol per liter) and acetic anhydride (0.25 mol per liter) for 10 minutes, dehydrated in ethanol, and air-dried. Sections were hybridized with a preproendothelin-1 complementary RNA (cRNA) probe labeled with sulfur-35 (1 × 10⁶ cpm per section) for 16 hours at 42 °C14. Unbound cRNA probe was removed by incubation in RNase solution (20 μg per milliliter) for 30 minutes at 42 °C in 2 × saline sodium citrate (SSC; 1 × SSC is 0.15 mol of sodium chloride and 0.015 mol of sodium citrate per liter, pH 7). This was followed by further washes in graded concentrations of SSC (from 2 × SSC to 0.1 × SSC) at temperatures ranging from 20 °C to 55 °C. Autoradiograms were exposed in light-tight boxes for 5 to 10 days at 4 °C, developed in D-19 developer (Kodak, Rochester, N.Y.), fixed, counterstained with hematoxylin, dehydrated, and mounted. Lung sections hybridized with a sense probe or sections treated with RNase solution before hybridization were used as negative controls for determining the specificity of the hybridization signals.

Simultaneous Localization of Endothelin-1 mRNA and Peptide

To examine whether endothelin-1-like immunoreactivity was localized to the cells that expressed the preproendothelin-1 mRNA, cryostat sections were rehydrated in phosphate-buffered saline, rendered permeable in proteinase K for seven minutes, immersed in 4 percent paraformaldehyde, and washed in phosphate-buffered saline. Subsequently, sections were hybridized with the radiolabeled preproendothelin-1 cRNA probe and washed as described above. After the last wash in 0.1 × SSC, sections were rinsed in phosphate-buffered saline and immunostained with the endothelin-1 antiserum as described above, then processed for autoradiography. The above method was a modification of that described by Hoefler et al23.

Northern Blot Analysis

For Northern blot analysis, total RNA was extracted from lung tissue from the patients with plexogenic pulmonary arteriopathy (group 1) and the patients with secondary pulmonary hypertension (group 2), and from the unused normal lung tissue of the organ donors. The RNA extraction and hybridization method has been described elsewhere24.

Statistical Analysis

The results are presented as means ±SE. The significance of differences between groups was assessed with a two-tailed Wilcoxon signed-rank test, and Bonferroni's correction was applied for multiple comparisons as appropriate25. Pulmonary vascular resistance was calculated in Wood units (the mean pulmonary arterial pressure minus the pulmonary-capillary wedge pressure in millimeters of mercury divided by the cardiac output in liters per minute), and total pulmonary resistance was calculated as the mean pulmonary arterial pressure divided by the cardiac output. The correlation between total pulmonary resistance and the grade of endothelin-1-like immunoreactivity (immunostaining) was assessed with ordinary least-squares linear regression techniques.

Results

Light-microscopical sections of tissue from the patients in group 1 revealed arteries with medial and intimal thickening (including onion-skinning), peripheral proliferation of muscle cells, and typical plexiform lesions with, in some instances, vasculitis18. Lung tissue from the patients in group 2, who had secondary pulmonary hypertension, showed changes typical of their respective underlying diseases and demonstrated variable degrees of medial thickening and intimal proliferation (i.e., grades 1 through 3).

Immunocytochemical analysis revealed very little endothelin-1-like immunoreactivity in the control subjects (Figure 1AFigure 1Endothelin-1-Like Immunoreactivity in Normal Lung Tissue and Lung Tissue from Patients with Plexogenic Pulmonary Arteriopathy (Group 1) and Secondary Pulmonary Hypertension (Group 2).). In contrast, substantial staining was observed in sections from the patients with pulmonary hypertension (Figure 1B, Figure 1C, Figure 1D, Figure 1E, Figure 1F, Figure 1G, and Figure 1H). The greatest degree of endothelin-1-like immunoreactivity was seen in the endothelium of muscular pulmonary arteries, particularly over vessels exhibiting severe morphologic changes (Fig. Figure 1B, Figure 1C, and Figure 1D). In addition, vascular immunostaining was seen in association with plexiform lesions (Figure 1E). The vascular endothelium of bronchial vessels also stained intensely (Figure 1F). Less commonly, endothelin-1-like immunoreactivity was observed in endothelial cells of capillaries and pulmonary veins and in neuroendocrine cells (Figure 1F), and in inflammatory cells, pulmonary epithelium, and vascular smooth-muscle cells of atherosclerotic pulmonary arteries (Figure 1G). In contrast, there was little or no staining in the vasculature of renal and myocardial tissues from the patients with pulmonary hypertension (data not shown).

In Figure 2Figure 2Mean (±SE) Level of Endothelin-1-Like Immunoreactivity in Vascular Endothelium of Lung Tissue from Two Groups of Controls (Panel A) and Two Groups of Patients with Pulmonary Hypertension (Panel B)., the degree of endothelin-1-like immunoreactivity in endothelial cells from each vascular region is compared in the patient groups. The grade of immunostaining was low in the controls, with the greatest immunoreactivity observed in elastic and muscular pulmonary arteries (0.4 ±0.2 and 0.2 ±0.1, respectively). This was in sharp contrast to the endothelin-1 immunostaining observed in elastic and muscular pulmonary arteries of the patients in both groups with pulmonary hypertension (2.73 ±0.22 and 2.74 ±0.15, respectively; P = 0.003); less pronounced increases in immunoreactivity were seen in the other vascular regions.

The distribution of vascular endothelin-1-like immunoreactivity was similar in the patients in groups 1 and 2 (Figure 2B). However, immunostaining was significantly greater in the muscular pulmonary arteries of the patients with plexogenic pulmonary arteriopathy (group 1) (mean grade, 3.3 ±0.1 vs. 2.4 ±0.2; P = 0.016). Furthermore, linear regression analysis indicated a significant correlation between endothelin-1-like immunoreactivity in muscular pulmonary arteries and total pulmonary resistance (a functional measurement of the severity of the disease) only in the patients with plexogenic pulmonary arteriopathy (P = 0.008). All four patients with interstitial fibrosis and pulmonary hypertension had substantial immunostaining for endothelin-1 in alveolar epithelial cells (mean grade for type II pneumocytes, 2.5 ±0.5) (Figure 1H). This immunostaining was not seen in the controls, and only rare pneumocytes stained in the patients with pulmonary hypertension without pulmonary fibrosis.

The majority of lung sections from the patients with pulmonary hypertension stained best with antiserum to endothelin-1 or stained equally well with endothelin-1 and big endothelin-1 antiserums. Seven patients, however, had stronger endothelin staining for the precursor than for the mature peptide (three in group 1 and four in group 2). Experiments with the negative controls showed no staining with the respective antiserums (Figure 3GFigure 3Expression of Endothelin-1 mRNA in the Vascular Endothelium of Pulmonary Arteries from Patients with Plexogenic Pulmonary Arteriopathy (Group 1) and Secondary Pulmonary Hypertension (Group 2).).

In situ hybridization revealed the expression of endothelin-1 mRNA in the patients with pulmonary hypertension, primarily in the vascular endothelium, whereas there were only scattered hybridization signals on autoradiographs from the control subjects (Figure 3H). Clusters of silver grains were found overlying vascular endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis in lung sections from the patients with pulmonary hypertension (Figure 3A, Figure 3B, and Figure 3C). The overall distribution of endothelin-1 mRNA relative to that of endothelin-1 immunostaining was demonstrated on sections that were both hybridized with the endothelin-1 cRNA probe and immunostained with endothelin-1 antiserums (Figure 3E and Figure 3F). Silver grains indicating the expression of endothelin-1 mRNA and the brown color of endothelin-1 immunostaining were seen mostly in the same cells, but on occasion endothelin-1 mRNA and the mature peptide were also expressed independently. There were no specific signals detectable on the negative-control sections hybridized with the sense probe or treated with RNase before hybridization with the endothelin-1 cRNA probe (Figure 3D). In addition, Northern blot analysis showed higher levels of preproendothelin-1 mRNA in lung tissue from the patients with plexogenic pulmonary arteriopathy and the patients with secondary pulmonary hypertension than in normal lung tissue.

Discussion

The present study provides direct evidence of increased local production of endothelin-1 in pulmonary hypertension and may explain earlier observations of increased circulating endothelin-1 levels in patients with this disorder16. Expression of endothelin-1 was found in the vessels that were most affected by the morphologic abnormalities of pulmonary hypertension. In addition, expression of endothelin-1 in alveolar epithelial cells was seen nearly exclusively in patients with pulmonary fibrosis, raising the possibility that increased production of endothelin-1 may be involved in the pathogenesis of a broad range of pulmonary diseases associated with cellular proliferation. Although the expression of endothelin-1 in the lungs of patients with pulmonary hypertension does not prove a cause-and-effect relation, such a relation is biologically plausible.

Although endothelin-1 immunostaining can only be graded semiquantitatively, the differences between the control group and the patients with pulmonary hypertension were striking. As in a previous report,14 there was little expression of endothelin-1 in the normal adult lung or in the pulmonary vasculature of patients with pulmonary disease but without pulmonary hypertension. This was in sharp contrast to the prominent endothelin-1-like immunoreactivity in specimens from the patients with pulmonary hypertension. Furthermore, the expression of preproendothelin-1 mRNA in the lungs of the patients with pulmonary hypertension, as demonstrated by in situ hybridization, matched closely the distribution of endothelin-1-like immunoreactivity, confirming that there is local production of endothelin-1 by the pulmonary vascular endothelium in this disorder.

The most intense endothelin-1 immunostaining was found in the vascular endothelium of the patients with plexogenic pulmonary arteriopathy (grades 4 through 6),18 many of whom had clinical findings consistent with a diagnosis of primary pulmonary hypertension according to the criteria of the National Heart, Lung, and Blood Institute19. This is in agreement with our earlier findings, based on the measurement of endothelin-1 plasma levels, which demonstrated the release of endothelin-1 across the pulmonary bed in patients with primary pulmonary hypertension16. Thus, the increased pulmonary vascular production and release of endothelin-1 in these patients point to a role for this vasoactive peptide in the functional and morphologic vascular abnormalities characteristic of pulmonary arteriopathy. Although there were no significant differences between groups 1 and 2 in pulmonary arterial pressure or pulmonary vascular resistance, only in group 1 was there a significant correlation between the increases in pulmonary resistance and the degree of endothelin-1-like immunoreactivity in pulmonary vessels. This finding suggests that the patients with primary pulmonary hypertension had not only a greater degree of endothelin-1 expression, but also a more specific association between increased local endothelin-1 production and the severity of the disease.

The distribution of endothelin-1-like immunoreactivity in the lung may provide further clues concerning its functional importance in patients with pulmonary hypertension. Regardless of patient group, the greatest degree of immunostaining occurred in the endothelium of elastic and muscular pulmonary arteries, which also demonstrated severe medial thickening and intimal proliferation, sometimes severe enough to produce luminal occlusion. To a lesser extent, staining was seen in pulmonary capillaries and veins and bronchial arteries, but no staining was found in systemic vessels in the myocardial and renal tissues of eight patients with pulmonary hypertension. Endothelin-1-like immunoreactivity was also seen in association with plexogenic lesions in the patients in group 1. This specific association of endothelin-1 expression with areas of abnormal pulmonary vascular architecture again supports the view that endothelin-1 contributes to the initiation or progression of these lesions. In a recent study, Stelzner et al.26 reported an increase in endothelin-1 production in the lung in rats with idiopathic pulmonary hypertension. Endothelin-1 is not only the most potent vasoconstrictor yet identified,7 but it has also been shown to stimulate the proliferation of smooth-muscle cells,8-10 and in vivo it may act in concert with other growth factors. Thus, from the standpoint of biologic activity and tissue distribution, endothelin-1 is a likely mediator of the functional and morphologic vascular abnormalities of pulmonary hypertension.

In addition to the vascular endothelium, limited expression of endothelin-1 was also found in neuroendocrine, inflammatory, and smooth-muscle cells. This is consistent with a previous report demonstrating the localization of endothelin-1-like immunoreactivity in pulmonary endocrine cells of developing and adult lungs14. Macrophages, mast cells, and polymorphonuclear leukocytes have also been shown to produce endothelin-1,27-29 the biosynthesis of which may be mediated by polymorphonuclear leukocytes29. Furthermore, the production of endothelin-1 in vascular smooth-muscle cells has been demonstrated in vitro30,31 and in vivo, particularly in atherosclerotic arteries32. However, the appearance of endothelin-1-like immunoreactivity in the alveolar epithelial cells of patients with pulmonary fibrosis was an unanticipated and intriguing finding. This was an extremely rare occurrence in patients with pulmonary hypertension without pulmonary fibrosis and was not seen in the control group. A role for endothelin-1 has been suggested in progressive systemic sclerosis,33,34 a disorder characterized by the abnormal production of connective tissue and fibrosis35. Indeed, it has been demonstrated that endothelin-1 can induce the proliferation of fibroblasts and increase the production of fibrous tissue in vitro33. The demonstration that alveolar epithelial cells express endothelin-1 in areas close to foci of fibrous replacement of alveolar structures suggests a role for this peptide in the pathogenesis of pulmonary fibrosis.

Our finding of striking increases in endothelin-1 mRNA and in the production of the mature peptide by pulmonary vascular endothelium provides compelling new evidence in support of the view that endothelin-1 contributes to the vascular abnormalities of pulmonary hypertension. The expression of this mitogenic peptide by alveolar epithelial cells in patients with pulmonary fibrosis raises the possibility that endothelin-1 has a broader role in pulmonary diseases associated with cellular proliferation or fibrosis. Although the precise definition of the pathophysiologic importance of endothelin-1 in these conditions awaits the availability of specific endothelin-1 antagonists or inhibitors for clinical use, the present study provides important new information about alterations in local pulmonary endothelin-1 synthesis and tissue distribution in human lung disease, which is an essential prerequisite for unraveling its biologic importance.

Supported by a grant (MT-11620) from the Medical Research Council of Canada and the Quebec Lung Association. Dr. Giaid was also supported by the Heart and Stroke Foundation of Canada.

We are indebted to Dr. L. Gaspar and the members of the Montreal Lung Transplant Program for their cooperation.

Source Information

From the Departments of Pathology (A.G., R.P.M., W.P.D.), Medicine (D.L., R.L., D.J.S.), and Surgery (H.S.), McGill University, Montreal; the Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas Southwest Medical Center, Dallas (M.Y.); Kyoto University, Kyoto, Japan (T.M.); and the Faculty of Medicine, Chiba University, Chiba, Japan (S.K.).

Address reprint requests to Dr. Giaid at the Dept. of Pathology, Montreal General Hospital, 1650 Cedar Ave., Montreal, QC H3G 14A, Canada.

References

References

1. 1

   Wagenvoort CA. Grading of pulmonary vascular lesions -- a reappraisal. Histopathology 1981;5:595-598
   CrossRef | Web of Science | Medline

2. 2

   Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958;20:557-570
   CrossRef | Web of Science | Medline

3. 3

   Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle to acetylcholine. Nature 1980;288:373-376
   CrossRef | Web of Science | Medline

4. 4

   Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-2018
   Web of Science | Medline

5. 5

   Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1979;30:293-331
   Web of Science

6. 6

   Griffith TM, Lewis MJ, Newby AC, Henderson AH. Endothelium-derived relaxing factor. J Am Coll Cardiol 1988;12:797-806
   CrossRef | Web of Science | Medline

7. 7

   Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415
   CrossRef | Web of Science | Medline

8. 8

   Dubin D, Pratt RE, Kooke JP, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Biol Med 1989;1:150-154
   

9. 9

   Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249-252[Erratum, FEBS Lett 1989;244:509.]
   CrossRef | Web of Science | Medline

10. 10

    Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-228
    CrossRef | Web of Science | Medline

11. 11

    Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem 1989;264:7856-7861
    Web of Science | Medline

12. 12

    Simonson MS, Wann S, Mene P, et al. Endothelin stimulates phospholipase C, Na⁺/H⁺ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708-712
    CrossRef | Web of Science | Medline

13. 13

    Muldoon LL, Rodland KD, Forsythe ML, Magun BE. Stimulation of phosphotidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J Biol Chem 1989;264:8529-8536
    Web of Science | Medline

14. 14

    Giaid A, Polak JM, Gaitonde V, et al. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung. Am J Respir Cell Mol Biol 1991;4:50-58
    Web of Science | Medline

15. 15

    de Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85:9797-9800
    CrossRef | Web of Science | Medline

16. 16

    Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469
    Web of Science | Medline

17. 17

    Reeves JT, Groves BM. Approach to the patient with pulmonary hypertension. In: Weit EK, Reeves JT, eds. Pulmonary hypertension. Mount Kisco, N.Y.: Futura, 1984:1-44.
    

18. 18

    Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-547
    Web of Science | Medline

19. 19

    Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223
    Web of Science | Medline

20. 20

    Shinmi O, Kimura S, Yoshizawa T, et al. Presence of endothelin-1 in porcine spinal cord: isolation and sequence determination. Biochem Biophys Res Commun 1989;162:340-346
    CrossRef | Web of Science | Medline

21. 21

    Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580
    CrossRef | Web of Science | Medline

22. 22

    Michel R, Hakim TS. Increased resistance in postobstructive pulmonary vasculopathy: structure-function relationships. J Appl Physiol 1991;71:601-610
    Web of Science | Medline

23. 23

    Hoefler H, Childers H, Montminy MR, Lechan RM, Goodman RH, Wolfe HJ. In situ hybridization methods for the detection of somatostatin mRNA in tissue sections using antisense RNA probes. Histochem J 1986;28:597-604
    CrossRef

24. 24

    Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A 1984;81:1991-1995
    CrossRef | Web of Science | Medline

25. 25

    Shortcuts and nonparametric methods. In: Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980:135-48.
    

26. 26

    Stelzner TJ, O'Brien RF, Yanagisawa M, et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992;262:L614-L620
    Web of Science | Medline

27. 27

    Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-1748
    CrossRef | Web of Science | Medline

28. 28

    Ehrenreich H, Burd PR, Rottem M, et al. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol 1992;4:147-156
    Medline

29. 29

    Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;174:613-618
    CrossRef | Web of Science | Medline

30. 30

    Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 1990;168:1303-1310
    CrossRef | Web of Science | Medline

31. 31

    Kanse SM, Takahashi K, Warren JB, et al. Production of endothelin by vascular smooth muscle cells. J Cardiovasc Pharmacol 1991;17:Suppl 7:S113-S116
    CrossRef | Web of Science | Medline

32. 32

    Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001
    Full Text | Web of Science | Medline

33. 33

    Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-983
    CrossRef | Web of Science | Medline

34. 34

    Yamane K, Kashiwagi H, Suzuki N, et al. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 1991;34:243-244
    CrossRef | Web of Science | Medline

35. 35

    Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9-17
    CrossRef | Web of Science | Medline

Citing Articles (454)

Citing Articles

1. 1

   Marlene Rabinovitch. 2012. Pulmonary Vascular Pathophysiology. , 71-80.
   CrossRef

2. 2

   Keiko Ohta-Ogo, Hiroyuki Hao, Hatsue Ishibashi-Ueda, Seiichi Hirota, Kazufumi Nakamura, Tohru Ohe, Hiroshi Ito. (2012) CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension. Pathology Internationalno-no
   CrossRef

3. 3

   David A. Zopf, Liomar A.A. das Neves, Kristen J. Nikula, Jinbao Huang, Peter B. Senese, Michael R. Gralinski. (2011) C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. European Journal of Pharmacology 670:1, 195-203
   CrossRef

4. 4

   Shingo Nemoto, Kumiko Taguchi, Takayuki Matsumoto, Katsuo Kamata, Tsuneo Kobayashi. (2011) Aminoguanidine normalizes ET-1-induced aortic contraction in type 2 diabetic Otsuka Long–Evans Tokushima Fatty (OLETF) rats by suppressing Jab1-mediated increase in ETA-receptor expression. Peptides
   CrossRef

5. 5

   Xiangbin Pan, Zhe Zheng, Shengshou Hu, Shoujun Li, Yingjie Wei, Yajuan Zhang, Xiansheng Cheng, Kai Ma. (2011) Mechanisms of Pulmonary Hypertension Related to Ventricular Septal Defect in Congenital Heart Disease. The Annals of Thoracic Surgery
   CrossRef

6. 6

   Vanessa Zambelli, Alessandro Santaniello, Francesca Fumagalli, Serge Masson, Raffaella Scorza, Lorenzo Beretta, Roberto Latini. (2011) Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. European Journal of Pharmacology 667:1-3, 287-291
   CrossRef

7. 7

   Gregory J. Keir, Tamera J. Corte. (2011) Pulmonary Hypertension in Interstitial Lung Disease. Clinical Pulmonary Medicine 18:5, 222-229
   CrossRef

8. 8

   Shunji Yoshida, Kunio Shirato, Ryutaro Shimamura, Norie Nakahara, Takayuki Iwase, Hiromu Nakajima. (2011) Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. Current Medical Research and Opinion 27:9, 1827-1834
   CrossRef

9. 9

   C. Tcherakian, É. Rivaud, É. Catherinot, D. Zucman, A.-C. Metivier, L.-J. Couderc. (2011) Hypertension artérielle pulmonaire liée à l’infection VIH : de la pression artérielle pulmonaire à l’interleukine-6. Revue de Pneumologie Clinique 67:4, 250-257
   CrossRef

10. 10

    Richa Agarwal, Mardi Gomberg-Maitland. (2011) Current therapeutics and practical management strategies for pulmonary arterial hypertension. American Heart Journal 162:2, 201-213
    CrossRef

11. 11

    Johann Strumpher, Eric Jacobsohn. (2011) Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management. Journal of Cardiothoracic and Vascular Anesthesia 25:4, 687-704
    CrossRef

12. 12

    Peter Oishi, Sanjeev A Datar, Jeffrey R Fineman. (2011) Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. Expert Opinion on Pharmacotherapy 12:12, 1845-1864
    CrossRef

13. 13

    Paolo Calabrò, Giuseppe Limongelli, Valeria Maddaloni, Carmine Dario Vizza, Michele D’Alto, Raffaella D’Alessandro, Roberto Poscia, Paola Argiento, Brunella Ziello, Roberto Badagliacca, Emanuele Romeo, Giuseppe Pacileo, Maria Giovanna Russo, Francesco Fedele, Raffaele Calabrò. (2011) Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Internal and Emergency Medicine
    CrossRef

14. 14

    Dermot S. O'Callaghan, Laurent Savale, David Montani, Xavier Jaïs, Olivier Sitbon, Gérald Simonneau, Marc Humbert. (2011) Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology 8:9, 526-538
    CrossRef

15. 15

    Susan Givens Bell. (2011) Bosentan. Neonatal Network: The Journal of Neonatal Nursing 30:4, 249-251
    CrossRef

16. 16

    Dermot S O'Callaghan, Laurent Savale, Azzedine Yaïci, Delphine Natali, Xavier Jaïs, Florence Parent, David Montani, Marc Humbert, Gérald Simonneau, Olivier Sitbon. (2011) Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 12:10, 1585-1596
    CrossRef

17. 17

    Gaurav Choudhary, Frederick Troncales, Douglas Martin, Elizabeth O. Harrington, James R. Klinger. (2011) Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. The Journal of Heart and Lung Transplantation 30:7, 827-833
    CrossRef

18. 18

    Dongmin Shao, John E.S. Park, Stephen J. Wort. (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacological Research 63:6, 504-511
    CrossRef

19. 19

    Tawfik Ayoub. (2011) Pulmonary hypertension in liver transplant. Current Opinion in Organ Transplantation 16:3, 331-337
    CrossRef

20. 20

    T. Hugues, F. Lemoigne, F. Macone, P. Cerboni, P. Gibelin. (2011) Hypertension artérielle pulmonaire disproportionnée : caractéristiques et pronostic d’une cohorte de patients niçois référés au laboratoire d’échocardiographie. Annales de Cardiologie et d'Angéiologie
    CrossRef

21. 21

    Robert F. Wideman, Krishna R. Hamal. (2011) Idiopathic pulmonary arterial hypertension: An avian model for plexogenic arteriopathy and serotonergic vasoconstriction. Journal of Pharmacological and Toxicological Methods 63:3, 283-295
    CrossRef

22. 22

    Stephen C Mathai, Paul M Hassoun. (2011) Pulmonary arterial hypertension associated with systemic sclerosis. Expert Review of Respiratory Medicine 5:2, 267-279
    CrossRef

23. 23

    Carlyne D Cool, Norbert F Voelkel, Todd Bull. (2011) Viral infection and pulmonary hypertension: is there an association?. Expert Review of Respiratory Medicine 5:2, 207-216
    CrossRef

24. 24

    George F Lasker, Jason H Maley, Edward A Pankey, Philip J Kadowitz. (2011) Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine 5:2, 153-161
    CrossRef

25. 25

    Sophie P. Toya, Asrar B. Malik. (2011) Role of endothelial injury in disease mechanisms and contribution of progenitor cells in mediating endothelial repair. Immunobiology
    CrossRef

26. 26

    Michelle J. Connolly, Philip I. Aaronson. (2011) Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 24:1, 1-14
    CrossRef

27. 27

    Emmanuel Guerrero, Dalia A. Banks, William R. Auger, Stuart W. Jamieson. (2011) CASE 1—2011: The Challenges Posed by a Complicated Pulmonary Thromboendarterectomy. Journal of Cardiothoracic and Vascular Anesthesia 25:1, 183-191
    CrossRef

28. 28

    M. Patricia George, Alexandra Brower, Heather Kling, Tim Shipley, Jan Kristoff, Todd A. Reinhart, Michael Murphey-Corb, Mark T. Gladwin, Hunter C. Champion, Alison Morris, Karen A. Norris. (2011) Pulmonary Vascular Lesions Are Common in SIV- and SHIV- env -Infected Macaques. AIDS Research and Human Retroviruses 27:2, 103-111
    CrossRef

29. 29

    Philipp Diehl, Miriam Aleker, Thomas Helbing, Verena Sossong, Martin Germann, Stephan Sorichter, Christoph Bode, Martin Moser. (2011) Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. Journal of Thrombosis and Thrombolysis 31:2, 173-179
    CrossRef

30. 30

    Yoshifumi Kawanabe, Surya M. Nauli. (2011) Endothelin. Cellular and Molecular Life Sciences 68:2, 195-203
    CrossRef

31. 31

    Rajamma Mathew. (2011) Cell-Specific Dual Role of Caveolin-1 in Pulmonary Hypertension. Pulmonary Medicine 2011, 1-12
    CrossRef

32. 32

    Jeanne Houtchens, Douglas Martin, James R. Klinger. (2011) Diagnosis and Management of Pulmonary Arterial Hypertension. Pulmonary Medicine 2011, 1-13
    CrossRef

33. 33

    Marie Billaud, Diana Dahan, Roger Marthan, Jean-Pierre Savineau, Christelle Guibert. (2011) Role of the gap junctions in the contractile response to agonists in pulmonary artery from two rat models of pulmonary hypertension. Respiratory Research 12:1, 30
    CrossRef

34. 34

    Walid Habre, Gergely Albu, Tibor Z Janosi, Fabienne Fontao, Britta S von Ungern-Sternberg, Maurice Beghetti, Ferenc Petak. (2011) Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. Respiratory Research 12:1, 58
    CrossRef

35. 35

    Nathan Dwyer, David Kilpatrick. (2011) Bosentan for the treatment of adult pulmonary hypertension. Future Cardiology 7:1, 19-37
    CrossRef

36. 36

    Satyan Lakshminrusimha, Vasanth H. Kumar. 2011. Diseases of Pulmonary Circulation. , 632-656.
    CrossRef

37. 37

    Bryan Corrin, Andrew G. Nicholson. 2011. Vascular disease. , 401-457.
    CrossRef

38. 38

    Stevan P Tofovic. (2010) Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease. Journal of Cardiovascular Pharmacology 56:6, 696-708
    CrossRef

39. 39

    Ying Yang, Mingyu Gao, Zhenlong Wu, Yuming Guo. (2010) Genistein attenuates low temperature induced pulmonary hypertension in broiler chicks by modulating endothelial function. European Journal of Pharmacology 649:1-3, 242-248
    CrossRef

40. 40

    Sherif Afifi, Shahriar Shayan, Abbas Al-Qamari. (2010) Pulmonary Hypertension and Right Ventricular Function. International Anesthesiology Clinics 47:1, 97-120
    CrossRef

41. 41

    Roman Gokhman, Pamela L Smithburger, Sandra L Kane-Gill, Amy L Seybert. (2010) Pharmacologic and Pharmacokinetic Rationale for Combination Therapy in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology 56:6, 686-695
    CrossRef

42. 42

    Stephen Y Chan, Joseph Loscalzo. 2010. Pulmonary Vascular Disease Related to Hemodynamic Stress in the Pulmonary Circulation. .
    CrossRef

43. 43

    Tamara Tajsic, Nicholas W. Morrell. 2010. Smooth Muscle Cell Hypertrophy, Proliferation, Migration and Apoptosis in Pulmonary Hypertension. .
    CrossRef

44. 44

    Meredith E Pugh, Anna R Hemnes. (2010) Pulmonary hypertension in women. Expert Review of Cardiovascular Therapy 8:11, 1549-1558
    CrossRef

45. 45

    Shuang Zhang, Yun Liu, Shouli Guo, Jianing Zhang, Xiaojie Chu, Chun Jiang, Daling Zhu. (2010) Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms. The Journal of Physiological Sciences 60:6, 389-397
    CrossRef

46. 46

    Tomonobu KOIZUMI, Kazuhisa URUSHIHATA, Masayuki HANAOKA, Kenji TSUSHIMA, Keisaku FUJIMOTO, Tadashige FUJII, Keishi KUBO. (2010) Iodine-123 metaiodobenzylguanidine scintigraphic assessment of pulmonary vascular status in patients with chronic obstructive pulmonary disease. Respirology 15:8, 1215-1219
    CrossRef

47. 47

    Marco Guazzi, Ross Arena. (2010) Pulmonary hypertension with left-sided heart disease. Nature Reviews Cardiology 7:11, 648-659
    CrossRef

48. 48

    Randy L. Webb, Gary M. Ksander. 2010. Endogenous Vasoactive Peptides. .
    CrossRef

49. 49

    Sevdalina Lambova, Ulf Müller-Ladner. (2010) Pulmonary arterial hypertension in systemic sclerosis. Autoimmunity Reviews 9:11, 761-770
    CrossRef

50. 50

    Marc Iglarz, Martine Clozel. (2010) At the heart of tissue: endothelin system and end-organ damage. Clinical Science 119:11, 453-463
    CrossRef

51. 51

    David F. Meoli, R. James White. (2010) Endothelin-1 induces pulmonary but not aortic smooth muscle cell migration by activating ERK1/2 MAP kinaseThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology 88:8, 830-839
    CrossRef

52. 52

    Arnold S. Kristof, Zhipeng You, Yin-Shan Han, Adel Giaid. (2010) Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. Peptides 31:8, 1511-1516
    CrossRef

53. 53

    Faquan Liang, Christopher B. Glascock, Denise L. Schafer, Jennifer Sandoval, LouAnn Cable, Lawrence Melvin, J. Craig Hartman, Kelly R. Pitts. (2010) Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteriesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology 88:8, 840-849
    CrossRef

54. 54

    George Chandy. (2010) Pulmonary hypertension associated with parenchymal lung disease. Canadian Journal of Cardiology 26, 21B-23B
    CrossRef

55. 55

    Nazzareno Galiè, Massimiliano Palazzini, Enri Leci, Alessandra Manes. (2010) Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. Revista Española de Cardiología 63:6, 708-724
    CrossRef

56. 56

    Maria A. Cavasin, Hillary Semus, Kelly Pitts, Yanyu Peng, Jennifer Sandoval, Joseph Chapo, Craig F. Plato. (2010) Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic ratsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology 88:6, 636-643
    CrossRef

57. 57

    Shripada Rao, David Bartle, Sanjay Patole. (2010) Current and future therapeutic options for persistent pulmonary hypertension in the newborn. Expert Review of Cardiovascular Therapy 8:6, 845-862
    CrossRef

58. 58

    H.-A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger. (2010) Aktuelle Therapie der pulmonal-arteriellen Hypertonie. Der Pneumologe 7:3, 192-199
    CrossRef

59. 59

    Ryutaro Yamanaka, Fumio Otsuka, Kazufumi Nakamura, Misuzu Yamashita, Hiroyuki Otani, Masaya Takeda, Yoshinori Matsumoto, Kengo F Kusano, Hiroshi Ito, Hirofumi Makino. (2010) Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertension Research 33:5, 435-445
    CrossRef

60. 60

    Paul Jurasz, David Courtman, Saeid Babaie, Duncan J. Stewart. (2010) Role of apoptosis in pulmonary hypertension: From experimental models to clinical trials. Pharmacology & Therapeutics 126:1, 1-8
    CrossRef

61. 61

    Steven H. Abman. (2010) Pulmonary hypertension in children: A historical overview. Pediatric Critical Care Medicine 11, S4-S9
    CrossRef

62. 62

    M. Salama, O. Andrukhova, M. A. Hoda, S. Taghavi, P. Jaksch, G. Heinze, W. Klepetko, S. Aharinejad. (2010) Concomitant Endothelin-1 Overexpression in Lung Transplant Donors and Recipients Predicts Primary Graft Dysfunction. American Journal of Transplantation 10:3, 628-636
    CrossRef

63. 63

    Meredith E Pugh, Anna R Hemnes. (2010) Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Women's Health 6:2, 285-296
    CrossRef

64. 64

    M Gomberg-Maitland, M L Maitland, R J Barst, L Sugeng, S Coslet, T J Perrino, L Bond, M E LaCouture, S L Archer, M J Ratain. (2010) A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension. Clinical Pharmacology & Therapeutics 87:3, 303-310
    CrossRef

65. 65

    Michele M. Hickey, Theresa Richardson, Tao Wang, Matias Mosqueira, Evguenia Arguiri, Hongwei Yu, Qian-Chun Yu, Charalambos C. Solomides, Edward E. Morrisey, Tejvir S. Khurana, Melpo Christofidou-Solomidou, M. Celeste Simon. (2010) The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. Journal of Clinical Investigation 120:3, 827-839
    CrossRef

66. 66

    Warren D. Rosenblum. (2010) Pulmonary Arterial Hypertension. Cardiology in Review 18:2, 58-63
    CrossRef

67. 67

    Ian Adatia, Lara Shekerdemian. (2010) The role of calcium channel blockers, steroids, anticoagulation, antiplatelet drugs, and endothelin receptor antagonists. Pediatric Critical Care Medicine 11, S46-S52
    CrossRef

68. 68

    Mantej K Chhina, Weir Nargues, Geraldine M Grant, Steven D Nathan. (2010) Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiology 6:1, 19-35
    CrossRef

69. 69

    Arata Nishimoto, Lingyun Lu, Misato Hayashi, Tadashi Nishiya, Takahiro Horinouchi, Soichi Miwa. (2010) Jab1 regulates levels of endothelin type A and B receptors by promoting ubiquitination and degradation. Biochemical and Biophysical Research Communications 391:4, 1616-1622
    CrossRef

70. 70

    Sheila G. Haworth, Marlene Rabinovitch. 2010. Pulmonary Circulation. , 117-141.
    CrossRef

71. 71

    Paul Jurasz, Douglas Ng, John T. Granton, David W. Courtman, Duncan J. Stewart. (2010) Elevated platelet angiostatin and circulating endothelial microfragments in idiopathic pulmonary arterial hypertension: A preliminary study. Thrombosis Research 125:1, 53-60
    CrossRef

72. 72

    Yong Soo Kwon, Su Young Chi, Hong Joon Shin, Eun Young Kim, Byeong Kab Yoon, Hee Jung Ban, In Jae Oh, Kyu Sik Kim, Young Chul Kim, Sung Chul Lim. (2010) Plasma C-Reactive Protein and Endothelin-1 Level in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. Journal of Korean Medical Science 25:10, 1487
    CrossRef

73. 73

    Kyoung Ah Lim, Kwan Chang Kim, Min-Sun Cho, Bo En Lee, Hae Soon Kim, Young Mi Hong. (2010) Gene Expression of Endothelin-1 and Endothelin Receptor A on Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment. Korean Circulation Journal 40:9, 459
    CrossRef

74. 74

    Caterina P. Minniti, Roberto F. Machado, Wynona A. Coles, Vandana Sachdev, Mark T. Gladwin, Gregory J. Kato. (2009) Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology 147:5, 737-743
    CrossRef

75. 75

    Marco Confalonieri, Metka Kodric, Cinzia Longo, Fabio G Vassallo. (2009) Bosentan for chronic thromboembolic pulmonary hypertension. Expert Review of Cardiovascular Therapy 7:12, 1503-1512
    CrossRef

76. 76

    Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery, Joan Albert Barberá, Maurice Beghetti, Paul Corris, Sean Gaine, J. Simon Gibbs, Miguel Ángel Gómez-Sánchez, Guillaume Jondeau, Walter Klepetko, Christian Opitz, Andrew Peacock, Lewis Rubin, Michael Zellweger, Gerald Simonneau. (2009) Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Española de Cardiología 62:12, 1464.e1-1464.e58
    CrossRef

77. 77

    E. Grünig. (2009) Antikoagulation bei pulmonaler arterieller Hypertonie. Der Pneumologe 6:6, 390-398
    CrossRef

78. 78

    Sarah Din, Padmini Sarathchandra, Magdi H. Yacoub, Adrian H. Chester. (2009) Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle. Vascular Pharmacology 51:5-6, 344-349
    CrossRef

79. 79

    Stephen C Mathai, Paul M Hassoun. (2009) Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Current Opinion in Rheumatology 21:6, 642-648
    CrossRef

80. 80

    Neetu Sud, Stephen M. Black. (2009) Endothelin-1 Impairs Nitric Oxide Signaling in Endothelial Cells Through a Protein Kinase Cδ-Dependent Activation of STAT3 and Decreased Endothelial Nitric Oxide Synthase Expression. DNA and Cell Biology 28:11, 543-553
    CrossRef

81. 81

    , N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, K. McGregor, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. Vardas, P. Widimsky, , U. Sechtem, N. Al Attar, F. Andreotti, M. Aschermann, R. Asteggiano, R. Benza, R. Berger, D. Bonnet, M. Delcroix, L. Howard, A. N. Kitsiou, I. Lang, A. Maggioni, J. E. Nielsen-Kudsk, M. Park, P. Perrone-Filardi, S. Price, M. T. S. Domenech, A. Vonk-Noordegraaf, J. L. Zamorano. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 30:20, 2493-2537
    CrossRef

82. 82

    Alisa Limsuwan, Pongsak Khowsathit. (2009) Assessment of pulmonary vasoreactivity in children with pulmonary hypertension. Current Opinion in Pediatrics 21:5, 594-599
    CrossRef

83. 83

    Carsten Höltke, Marilyn P. Law, Stefan Wagner, Klaus Kopka, Andreas Faust, Hans-Jörg Breyholz, Otmar Schober, Christoph Bremer, Burkhard Riemann, Michael Schäfers. (2009) PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies. Bioorganic & Medicinal Chemistry 17:20, 7197-7208
    CrossRef

84. 84

    Sohita Dhillon, Gillian M. Keating. (2009) Bosentan. American Journal Cardiovascular Drugs 9:5, 331-350
    CrossRef

85. 85

    S. Rafeq, A. M. Shah, I. R. Preston. (2009) Biomarkers in pulmonary arterial hypertension. International Journal of Clinical Practice 63, 36-41
    CrossRef

86. 86

    R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger, H.A. Ghofrani. (2009) Therapie der pulmonalarteriellen Hypertonie. Der Internist 50:9, 1101-1110
    CrossRef

87. 87

    David Montani, Marie-Camille Chaumais, Laurent Savale, Delphine Natali, Laura C. Price, Xavier Jaïs, Marc Humbert, Gérald Simonneau, Olivier Sitbon. (2009) Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy 26:9, 813-825
    CrossRef

88. 88

    Eiji Suzuki, Hyo Kyozuka, Toru Nishida, Takashi Kanno, Hiromasa Ohira. (2009) Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan. Modern Rheumatology 19:4, 447-451
    CrossRef

89. 89

    Annick Préfontaine, Angelino Calderone, Jocelyn Dupuis. (2009) Downregulation of the Endothelin System of Lung Myofibroblasts in Congestive Heart Failure. Journal of Cardiovascular Pharmacology 54:2, 147-153
    CrossRef

90. 90

    Nedim Selimovic, Bert Andersson, Claes-Håkan Bergh, Egidija Sakiniene, Hans Carlsten, Bengt Rundqvist. (2009) Endothelin-1 Across the Lung Circulation in Patients With Pulmonary Arterial Hypertension and Influence of Epoprostenol Infusion. The Journal of Heart and Lung Transplantation 28:8, 808-814
    CrossRef

91. 91

    T.H. Chapman, M. Wilde, A. Sheth, B.P. Madden. (2009) Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?. Vascular Pharmacology 51:2-3, 90-95
    CrossRef

92. 92

    Zhi-Cheng Jing, Xi-Qi Xu, David B. Badesch, Xin Jiang, Yan Wu, Jin-Ming Liu, Yong Wang, Lei Pan, Hui-Ping Li, Jie-Lin Pu, Zhuo-Li Zhang, Yue-Jin Yang. (2009) Pulmonary function testing in patients with pulmonary arterial hypertension. Respiratory Medicine 103:8, 1136-1142
    CrossRef

93. 93

    Chao Liu, Junmin Chen, Yanqiu Gao, Bao Deng, Kunshen Liu, Chao Liu. 2009. Endothelin receptor antagonists for pulmonary arterial hypertension. .
    CrossRef

94. 94

    Yue Qi, Wen-Quan Niu, Tong-Chun Zhu, Jing-Liang Liu, Wei-Ya Dong, Ying Xu, Shou-Quan Ding, Cheng-Bing Cui, Yun-Jun Pan, Guo-Shu Yu, Wen-Yu Zhou, Chang-Chun Qiu. (2009) Genetic interaction of Hsp70 family genes polymorphisms with high-altitude pulmonary edema among Chinese railway constructors at altitudes exceeding 4000 meters. Clinica Chimica Acta 405:1-2, 17-22
    CrossRef

95. 95

    You-Yang Zhao, Yidan D. Zhao, Muhammad K. Mirza, Julia H. Huang, Hari-Hara S.K. Potula, Steven M. Vogel, Viktor Brovkovych, Jason X.-J. Yuan, John Wharton, Asrar B. Malik. (2009) Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. Journal of Clinical Investigation 119:7, 2009-2018
    CrossRef

96. 96

    Terence K. Trow, Darren B. Taichman. (2009) Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism. Respiratory Medicine 103:7, 951-962
    CrossRef

97. 97

    S. S. Pullamsetti, R. T. Schermuly. (2009) Endothelin receptor antagonists in preclinical models of pulmonary hypertension. European Journal of Clinical Investigation 39, 3-13
    CrossRef

98. 98

    Olaf Mercier, Edouard Sage, Marc de Perrot, Ly Tu, Elisabeth Marcos, Benoît Decante, Bruno Baudet, Philippe Hervé, Philippe Dartevelle, Saadia Eddahibi, Elie Fadel. (2009) Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. The Journal of Thoracic and Cardiovascular Surgery 137:6, 1538-1546
    CrossRef

99. 99

    Panayiota Papadopoulos, Nicolas Bousette, Wisam Al-Ramli, Zhipeng You, David J. Behm, Eliot H. Ohlstein, Stephen M. Harrison, Stephen A. Douglas, Adel Giaid. (2009) Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: Effect of UT antagonism in ApoE knockout mice fed with Western diet. Atherosclerosis 204:2, 395-404
    CrossRef

100. 100

     N. J. Davie, R. T. Schermuly, N. Weissmann, F. Grimminger, H. A. Ghofrani. (2009) The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. European Journal of Clinical Investigation 39, 38-49
     CrossRef

101. 101

     D. Langleben, P. Cacoub. (2009) A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. European Journal of Clinical Investigation 39, 27-31
     CrossRef

102. 102

     Joan Albert Barberà, Isabel Blanco. (2009) Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Drugs 69:9, 1153-1171
     CrossRef

103. 103

     Robyn J. Barst, Duncan Stewart. (2009) Conventional and targeted medical therapies. Cardiology in the Young 19:S1, 28
     CrossRef

104. 104

     Pinar Yildiz. (2009) Molecular mechanisms of pulmonary hypertension. Clinica Chimica Acta 403:1-2, 9-16
     CrossRef

105. 105

     Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology 53:17, 1573-1619
     CrossRef

106. 106

     Paul M Hassoun. (2009) Therapies for scleroderma-related pulmonary arterial hypertension. Expert Review of Respiratory Medicine 3:2, 187-196
     CrossRef

107. 107

     Karen M. Olsson, Marius M. Hoeper. (2009) Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discovery Today 14:5-6, 284-290
     CrossRef

108. 108

     Steven H. Abman. (2009) Role of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension. Annual Review of Medicine 60:1, 13-23
     CrossRef

109. 109

     M. D. McGoon, G. C. Kane. (2009) Pulmonary Hypertension: Diagnosis and Management. Mayo Clinic Proceedings 84:2, 191-207
     CrossRef

110. 110

     M. G.J. Duffels, M. Hardziyenka, S. Surie, R. H.A.C.M de Bruin-Bon, E. S. Hoendermis, A. P.J. van Dijk, B. J. Bouma, H. L. Tan, R. M.F. Berger, P. Bresser, B. J.M. Mulder. (2009) Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension. European Journal of Echocardiography 10:3, 433-438
     CrossRef

111. 111

     Dae-Won Sohn, Hyung-Kwan Kim, Myung-A Kim, Yeong-Wook Song, Chung-Il Noh, Duk-Kyung Kim, I-Seok Kang, Hojoong Kim, Sang-Do Lee, Young-Hwue Kim, Ho-Joong Youn, Namsik Chung, Jae-Young Choi, Jae-Bum Jun, Jinho Shin. (2009) Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension. Korean Circulation Journal 39:3, 105
     CrossRef

112. 112

     Erika B. Rosenzweig, Robyn J. Barst. (2009) Pulmonary arterial hypertension in children: A Medical Update. The Indian Journal of Pediatrics 76:1, 77-81
     CrossRef

113. 113

     Gregory P. Star, Michele Giovinazzo, David Langleben. (2009) Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascular Pharmacology 50:1-2, 45-50
     CrossRef

114. 114

     María Asunción Nieto Barbero. (2009) EPOC e hipertensión pulmonar. Archivos de Bronconeumología 45, 24-30
     CrossRef

115. 115

     Christopher J. Rhodes, Alexandra Davidson, J. Simon R. Gibbs, John Wharton, Martin R. Wilkins. (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacology & Therapeutics 121:1, 69-88
     CrossRef

116. 116

     Roberto Rodríguez-Roisin, Joan Albert Barberà. 2009. Pulmonary Vessels. , 249-256.
     CrossRef

117. 117

     Justin S. W. Taylor, Julian P. J. Halcox. (2008) PDE5 inhibitors and pulmonary hypertension. Current Sexual Health Reports 5:4, 171-178
     CrossRef

118. 118

     Carmine Dario Vizza, Claudio Letizia, Luigi Petramala, Roberto Badagliacca, Roberto Poscia, Enrico Zepponi, Eleonora Crescenzi, Alfred Nona, Giulia Benedetti, Fabio Ferrante, Susanna Sciomer, Francesco Fedele. (2008) Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regulatory Peptides 151:1-3, 48-53
     CrossRef

119. 119

     Marc Humbert, David Montani, Frédéric Perros, Peter Dorfmüller, Serge Adnot, Saadia Eddahibi. (2008) Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascular Pharmacology 49:4-6, 113-118
     CrossRef

120. 120

     Robert P Frantz. (2008) Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence. Future Cardiology 4:5, 459-468
     CrossRef

121. 121

     Marc Humbert. (2008) Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 22:Suppl 3, S41-S47
     CrossRef

122. 122

     Raymond L. Benza. (2008) Pulmonary Hypertension Associated with Sickle Cell Disease: Pathophysiology and Rationale for Treatment. Lung 186:4, 247-254
     CrossRef

123. 123

     P. D'Orléans-Juste, M. Houde, G.A. Rae, G. Bkaily, E. Carrier, E. Simard. (2008) Endothelin-1 (1–31): From chymase-dependent synthesis to cardiovascular pathologies. Vascular Pharmacology 49:2-3, 51-62
     CrossRef

124. 124

     Saiprasad M. Zemse, Rob H.P. Hilgers, G. Bryan Simkins, R. Daniel Rudic, R. Clinton Webb. (2008) Restoration of endothelin-1-induced impairment in endothelium-dependent relaxation by interleukin-10 in murine aortic ringsThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology 86:8, 557-565
     CrossRef

125. 125

     Marlene Rabinovitch. (2008) Molecular pathogenesis of pulmonary arterial hypertension. Journal of Clinical Investigation 118:7, 2372-2379
     CrossRef

126. 126

     Dermot S. O'Callaghan. (2008) Emerging treatments for pulmonary arterial hypertension. The Clinical Respiratory Journal 2:3, 132-140
     CrossRef

127. 127

     Eri Ochiai, Katsuhiko Kamei, Akira Watanabe, Masaru Nagayoshi, Yuji Tada, Tetsutaro Nagaoka, Koichi Sato, Ayaka Sato, Kazutoshi Shibuya. (2008) Inhalation of Stachybotrys chartarum causes pulmonary arterial hypertension in mice. International Journal of Experimental Pathology 89:3, 201-208
     CrossRef

128. 128

     Erika B Rosenzweig, Robyn J Barst. (2008) Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics 20:3, 288-293
     CrossRef

129. 129

     Nika Skoro-Sajer, Irene Lang. (2008) Treprostinil for the treatment of pulmonary hypertension. Expert Opinion on Pharmacotherapy 9:8, 1415-1420
     CrossRef

130. 130

     Tsvetomir Loukanov, Raoul Arnold, Jasmin Gross, Christian Sebening, Homa Klimpel, Joachim Eichhorn, Katharina Hoss, Herbert E. Ulmer, Matthias Kark, Matthias Gorenflo. (2008) Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair. Clinical Research in Cardiology 97:6, 383-388
     CrossRef

131. 131

     Patrik Rossi, Björn Persson, Piet J. M. Boels, Anders Arner, Eddie Weitzberg, Anders Oldner. (2008) Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction. Intensive Care Medicine 34:5, 873-880
     CrossRef

132. 132

     Thomas G. Smith, Peter A. Robbins, Peter J. Ratcliffe. (2008) The human side of hypoxia-inducible factor. British Journal of Haematology 141:3, 325-334
     CrossRef

133. 133

     Judy W.M. Cheng. (2008) Ambrisentan for the management of pulmonary arterial hypertension. Clinical Therapeutics 30:5, 825-833
     CrossRef

134. 134

     P. Cacoub, Z. Amoura, D. Langleben. (2008) La prise en charge thérapeutique de l’hypertension artérielle pulmonaire par les antagonistes des récepteurs de l’endothéline en 2008. La Revue de Médecine Interne 29:4, 283-289
     CrossRef

135. 135

     Kelly M. Chin, Lewis J. Rubin. (2008) Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 51:16, 1527-1538
     CrossRef

136. 136

     Rosario Rossi, Annachiara Nuzzo, Antonella Lattanzi, Francesca Coppi, Maria Grazia Modena. (2008) Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 21:1, 172-177
     CrossRef

137. 137

     Myung H. Park. (2008) Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheterization and Cardiovascular Interventions 71:2, 205-213
     CrossRef

138. 138

     Yasuyuki KAMATA, Masahiro IWAMOTO, Seiji MINOTA. (2008) Treatment of pulmonary hypertension associated with connective tissue disease. Japanese Journal of Clinical Immunology 31:6, 424-431
     CrossRef

139. 139

     Eli Gabbay, Robert G. Weintraub, Lewis J. Rubin. 2008. Pulmonary Arterial Hypertension. , 759-771.
     CrossRef

140. 140

     Raymond J. Foley, Mark L. Metersky. (2008) Successful Treatment of Sarcoidosis-Associated Pulmonary Hypertension with Bosentan. Respiration 75:2, 211-214
     CrossRef

141. 141

     Nazzareno Galie, Alessandra Manes, Massimiliano Palazzini, Luca Negro, Alessandro Marinelli, Simona Gambetti, Elisabetta Mariucci, Andrea Donti, Angelo Branzi, Fernando M Picchio. (2008) Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger???s Syndrome. Drugs 68:8, 1049-1066
     CrossRef

142. 142

     James A Driscoll, Murali M Chakinala. (2008) Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 9:1, 65-81
     CrossRef

143. 143

     Steven H. Abman. 2008. Cor Pulmonale and Pulmonary Complications of Cardiac Disease. , 735-757.
     CrossRef

144. 144

     Peter Kabunga, Gerry Coghlan. (2008) Endothelin Receptor Antagonism. Drugs 68:12, 1635-1645
     CrossRef

145. 145

     Stephen Y. Chan, Joseph Loscalzo. (2008) Pathogenic mechanisms of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 44:1, 14-30
     CrossRef

146. 146

     Marc Iglarz, Martine Clozel. (2007) Mechanisms of ET-1-induced Endothelial Dysfunction. Journal of Cardiovascular Pharmacology 50:6, 621-628
     CrossRef

147. 147

     Gustavo A. Heresi, Raed A. Dweik. (2007) Pulmonary Hypertension: Evaluation and Management. Comprehensive Therapy 33:3, 150-161
     CrossRef

148. 148

     Junji Egawa, Satoki Inoue, Takeaki Shinjo, Hitoshi Furuya. (2007) Pulmonary hypertension due to unknown causes in liver resection. Journal of Anesthesia 21:4, 513-515
     CrossRef

149. 149

     Allison J. Sutherland, Robert S. Ware, Clay Winterford, John F. Fraser. (2007) The Endothelin Axis and Gelatinase Activity in Alveolar Macrophages After Brain-stem Death Injury: A Pilot Study. The Journal of Heart and Lung Transplantation 26:10, 1040-1047
     CrossRef

150. 150

     C. Denton, C. Black. (2007) Blocage de l'endothéline dans la sclérodermie systémique : rationnel et bénéfice clinique. La Revue de Médecine Interne 28, S214-S220
     CrossRef

151. 151

     Robert Naeije, Sandrine Huez. (2007) Expert opinion on available options treating pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:14, 2247-2265
     CrossRef

152. 152

     Subramanian Kannan, Sivaprakash, Dhanasegaran Sivanesan Egambaram, Raji Venkatram. (2007) Spontaneous aortocaval fistula — presenting as severe pulmonary hypertension. Indian Journal of Thoracic and Cardiovascular Surgery 23:3, 218-220
     CrossRef

153. 153

     John H. Newman, Santwana Kar, Peter Kirkpatrick. (2007) Ambrisentan. Nature Reviews Drug Discovery 6:9, 697-698
     CrossRef

154. 154

     Matthias Gorenflo, Michael V Ullmann, Esther Herpel, Stephan Neumayer, Ralf Dieckmann, Sueha Demirakca, Homa Klimpel, Siegfried Hagl, Martha Maria Gebhard. (2007) Atrasentan Treatment of Pulmonary Vascular Disease in Piglets With Increased Pulmonary Blood Flow. Journal of Cardiovascular Pharmacology 50:3, 286-292
     CrossRef

155. 155

     Xun Tan, Song-Hua Hu, Xiao-Long Wang. (2007) Possible role of nitric oxide in the pathogenesis of pulmonary hypertension in broilers: a synopsis. Avian Pathology 36:4, 261-267
     CrossRef

156. 156

     Rahman Shah. (2007) Endothelins in health and disease. European Journal of Internal Medicine 18:4, 272-282
     CrossRef

157. 157

     Eiichiro Mawatari, Minoru Hongo, Akio Sakai, Fumiko Terasawa, Masafumi Takahashi, Yoshikazu Yazaki, Osamu Kinoshita, Uichi Ikeda. (2007) AMLODIPINE PREVENTS MONOCROTALINE-INDUCED PULMONARY ARTERIAL HYPERTENSION AND PROLONGS SURVIVAL IN RATS INDEPENDENT OF BLOOD PRESSURE LOWERING. Clinical and Experimental Pharmacology and Physiology 34:7, 594-600
     CrossRef

158. 158

     Reda E Girgis, Richard AF Dixon. (2007) Sitaxsentan for the treatment of pulmonary arterial hypertension. Future Cardiology 3:4, 377-385
     CrossRef

159. 159

     Matthias Gorenflo, Esther Herpel, Michael V. Ullmann, Karoline Röhlig, Sueha Demirakca, Homa Klimpel, Siegfried Hagl, Martha Maria Gebhard, Philipp A. Schnabel. (2007) Pulmonary vascular changes in piglets with increased pulmonary blood flow and pressure. Virchows Archiv 450:6, 643-652
     CrossRef

160. 160

     Paul V. Santos Estrella, Yih Chang Lin, Sandra V. Navarra. (2007) Pulmonary arterial hypertension among Filipino patients with connective tissue diseases. Modern Rheumatology 17:3, 224-227
     CrossRef

161. 161

     M. Canuet, A. Chaouat. (2007) Le bosentan améliore les capacities d’exercice et l’état hémodynamique pulmonaire des patients ayant un syndrome d’Eisenmenger. Revue des Maladies Respiratoires 24, 99-100
     CrossRef

162. 162

     Birger Wolff, Sven Lodziewski, Tom Bollmann, Christian F. Opitz, Ralf Ewert. (2007) Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. American Heart Journal 153:6, 1088.e1-1088.e7
     CrossRef

163. 163

     Lucy Waite, Rajan Madhok. (2007) Pulmonary hypertension in systemic sclerosis: a review of diagnostic and therapeutic options. Future Rheumatology 2:3, 279-286
     CrossRef

164. 164

     Aniket Puri, Michael D McGoon, Sudhir S Kushwaha. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nature Clinical Practice Cardiovascular Medicine 4:6, 319-329
     CrossRef

165. 165

     Alejandro Macchia, Roberto Marchioli, RosaMaria Marfisi, Marco Scarano, Giacomo Levantesi, Luigi Tavazzi, Gianni Tognoni. (2007) A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal 153:6, 1037-1047
     CrossRef

166. 166

     V. Roig Figueroa, A. Herrero Pérez, E. Abad Lecha, I. Ramos Cancelo, D. Vielba Ramos. (2007) Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases. Current Medical Research and Opinion 23:s2, S49-S53
     CrossRef

167. 167

     Anne V. LaRaia, Aaron B. Waxman. (2007) Pulmonary Arterial Hypertension: Evaluation and Management. Southern Medical Journal 100:4, 393-399
     CrossRef

168. 168

     Hong Mu, Hong Chai, Peter H. Lin, Qizhi Yao, Changyi Chen. (2007) Current Update on HIV-associated Vascular Disease and Endothelial Dysfunction. World Journal of Surgery 31:4, 632-643
     CrossRef

169. 169

     Dermot O'Callaghan, Sean P. Gaine. (2007) Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 169-185
     CrossRef

170. 170

     Rubin M. Tuder, John C. Marecki, Amy Richter, Iwona Fijalkowska, Sonia Flores. (2007) Pathology of Pulmonary Hypertension. Clinics in Chest Medicine 28:1, 23-42
     CrossRef

171. 171

     Reda E. Girgis, Stephen C. Mathai. (2007) Pulmonary Hypertension Associated with Chronic Respiratory Disease. Clinics in Chest Medicine 28:1, 219-232
     CrossRef

172. 172

     S.A. van Wolferen, K. Grünberg, A. Vonk Noordegraaf. (2007) Diagnosis and management of pulmonary hypertension over the past 100 years. Respiratory Medicine 101:3, 389-398
     CrossRef

173. 173

     David Langleben. (2007) Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 117-125
     CrossRef

174. 174

     Eric D. Austin, James E. Loyd. (2007) Genetics and Mediators in Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 43-57
     CrossRef

175. 175

     Wayne L. Strauss, Jeffrey D. Edelman. (2007) Prostanoid Therapy for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 127-142
     CrossRef

176. 176

     BENOIT RONDELET, FRAN??OIS KERBAUL, GABRIELA FLORES VIVIAN, IVES HUBLOUE, SANDRINE HUEZ, PIERRE FESLER, MYRIAM REMMELINK, SERGE BRIMIOUILLE, ISABELLE SALMON, ROBERT NAEIJE. (2007) Sitaxsentan for the Prevention of Experimental Shunt-Induced Pulmonary Hypertension. Pediatric Research 61:3, 284-288
     CrossRef

177. 177

     BKS Sastry. (2007) Pharmacologic treatment for pulmonary arterial hypertension. Current Opinion in Internal Medicine 6:1, 11-18
     CrossRef

178. 178

     Marlene Rabinovitch. (2007) Pathobiology of Pulmonary Hypertension. Annual Review of Pathology: Mechanisms of Disease 2:1, 369-399
     CrossRef

179. 179

     Mohammed M. Minhaj, David A. Zvara, Pankaj Nayyar, Andrew Maslow. (2007) Case 1—2007. Journal of Cardiothoracic and Vascular Anesthesia 21:1, 133-143
     CrossRef

180. 180

     Bing Cui, Feng Yu, De-Zai Dai, Tian-Tai Zhang, Xiao-Yun Tang, Yin Dai. (2007) CPU0123, a novel endothelin receptor antagonist, relieves hypoxic pulmonary hypertension in rats by suppressing excessive ET-ROS pathway. Drug Development Research 68:1, 42-50
     CrossRef

181. 181

     Markus P. Schneider, Erika I. Boesen, David M. Pollock. (2007) Contrasting Actions of Endothelin ET _A and ET _B Receptors in Cardiovascular Disease. Annual Review of Pharmacology and Toxicology 47:1, 731-759
     CrossRef

182. 182

     Shigetake Sasayama, Toru Satoh, Tohru Izumi, Shunji Yoshida, Shingo Kyotani, Nobuhiro Tahara. (2007) Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. Current Medical Research and Opinion 23:2, 395-400
     CrossRef

183. 183

     Yoshihiro Fukumoto, Shunsuke Tawara, Hiroaki Shimokawa. (2007) Recent Progress in the Treatment of Pulmonary Arterial Hypertension: Expectation for Rho-Kinase Inhibitors. The Tohoku Journal of Experimental Medicine 211:4, 309-320
     CrossRef

184. 184

     Seung Won Ra, Sang-Do Lee. (2007) Cellular and Molecular Pathophysiology of Idiopathic Pulmonary Arterial Hypertension. Tuberculosis and Respiratory Diseases 63:6, 475
     CrossRef

185. 185

     Takahiro Imaizumi, Jun Nejima, Kaname Kiuchi, Shinhiro Takeda, Yoshihiko Seino, Keiji Tanaka, Teruo Takano. (2007) Dynamics and Source of Endothelin-1 and Interleukin-6 Following Coronary Reperfusion in Patients with Acute Myocardial Infarction. Journal of Nippon Medical School 74:2, 131-147
     CrossRef

186. 186

     Yoshimune Hiramoto, Wataru Shioyama, Tadashi Kuroda, Mitsuru Masaki, Shoko Sugiyama, Kitaro Okamoto, Hisao Hirota, Yasushi Fujio, Masatsugu Hori, Keiko Yamauchi-Takihara. (2007) Effect of Bosentan on Plasma Endothelin-1 Concentration in Patients With Pulmonary Arterial Hypertension. Circulation Journal 71:3, 367-369
     CrossRef

187. 187

     Masahito Sakuma, Jun Demachi, Jun Suzuki, Jun Nawata, Tohru Takahashi, Kunio Shirato. (2007) Proximal Pulmonary Artery Aneurysms in Patients with Pulmonary Artery Hypertension: Complicated Cases. Internal Medicine 46:21, 1789-1793
     CrossRef

188. 188

     Avrum Jacobs, Ioana R. Preston, Mardi Gomberg-Maitland. (2006) Endothelin receptor antagonism in pulmonary arterial hypertension – a role for selective ET _A inhibition?. Current Medical Research and Opinion 22:12, 2567-2574
     CrossRef

189. 189

     Stephen M. Black, Jeffrey R. Fineman. (2006) Oxidative and nitrosative stress in pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide. Vascular Pharmacology 45:5, 308-316
     CrossRef

190. 190

     Teresa De Marco. (2006) Pulmonary Arterial Hypertension and Women. Cardiology in Review 14:6, 312-318
     CrossRef

191. 191

     S.G. Haworth. (2006) Role of the endothelium in pulmonary arterial hypertension. Vascular Pharmacology 45:5, 317-325
     CrossRef

192. 192

     Erika B Rosenzweig. (2006) Emerging treatments for pulmonary arterial hypertension. Expert Opinion on Emerging Drugs 11:4, 609-619
     CrossRef

193. 193

     Eric Hachulla, David Launay, Marc Humbert. (2006) Bosentan for the treatment of scleroderma. Future Rheumatology 1:5, 549-562
     CrossRef

194. 194

     Richard N. Channick, Horst Olschewski, Werner Seeger, Ted Staub, Robert Voswinckel, Lewis J. Rubin. (2006) Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 48:7, 1433-1437
     CrossRef

195. 195

     Marius M Hoeper. (2006) Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?. Nature Clinical Practice Cardiovascular Medicine 3:10, 536-537
     CrossRef

196. 196

     Makoto Sahara, Toshiyuki Takahashi, Yasushi Imai, Toshiaki Nakajima, Atsushi Yao, Toshihiro Morita, Yasunobu Hirata, Ryozo Nagai. (2006) New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs and Therapy 20:5, 377-386
     CrossRef

197. 197

     Kiran K. Khush, Teresa De Marco, Kalpesh T. Vakharia, Cynthia Harmon, Jeffrey R. Fineman, Kanu Chatterjee, Andrew D. Michaels. (2006) Nesiritide Acutely Increases Pulmonary and Systemic Levels of Nitric Oxide in Patients With Pulmonary Hypertension. Journal of Cardiac Failure 12:7, 507-513
     CrossRef

198. 198

     D. Pittrow, W. Kirch. (2006) Dual endothelin receptor antagonism in pulmonary arterial hypertension. European Journal of Clinical Investigation 36:s3, v-vi
     CrossRef

199. 199

     Mordechai Yigla, Zaid Abassi, Shimon A. Reisner, Farid Nakhoul. (2006) Pulmonary Hypertension in Hemodialysis Patients: An Unrecognized Threat. Seminars in Dialysis 19:5, 353-357
     CrossRef

200. 200

     G. Giannelli, F. Iannone, F. Marinosci, G. Lapadula, S. Antonaci. (2006) Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. European Journal of Clinical Investigation 36:s3, 73-77
     CrossRef

201. 201

     W. Neuhofer, V. Gulberg, A. L. Gerbes. (2006) Endothelin and endothelin receptor antagonism in portopulmonary hypertension. European Journal of Clinical Investigation 36:s3, 54-61
     CrossRef

202. 202

     O. Sitbon, M. Beghetti, J. Petit, L. Iserin, M. Humbert, V. Gressin, G. Simonneau. (2006) Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. European Journal of Clinical Investigation 36:s3, 25-31
     CrossRef

203. 203

     C. F. Opitz, R. Ewert. (2006) Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension. European Journal of Clinical Investigation 36:s3, 1-9
     CrossRef

204. 204

     M. Beghetti. (2006) Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. European Journal of Clinical Investigation 36:s3, 16-24
     CrossRef

205. 205

     Sabina A Antoniu. (2006) Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opinion on Pharmacotherapy 7:13, 1801-1810
     CrossRef

206. 206

     D. J. PADILLA, T. S. EPP, P. McDONOUGH, D. J. MARLIN, H. H. ERICKSON, D. C. POOLE. (2006) Effects of a specific endothelin-1A antagonist on exercise-induced pulmonary haemorrhage (EIPH) in Thoroughbred horses. Equine Veterinary Journal 38:S36, 198-203
     CrossRef

207. 207

     Omar A. Minai, Alejandro C. Arroliga. (2006) Long-term Results After Addition of Sildenafil in Idiopathic PAH Patients on Bosentan. Southern Medical Journal 99:8, 880-883
     CrossRef

208. 208

     Chao Liu, Junmin Chen, Chao Liu. 2006. Endothelin receptor antagonists for pulmonary arterial hypertension. .
     CrossRef

209. 209

     Zaid Abassi, Farid Nakhoul, Eliyahu Khankin, Shimon A Reisner, Mordechai Yigla. (2006) Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Current Opinion in Nephrology and Hypertension 15:4, 353-360
     CrossRef

210. 210

     K. Ahmadi-Simab, W. L. Gross. (2006) Pulmonale arterielle Hypertonie bei Kollagenosen: Klinik, Epidemiologie, Pathogenese, Diagnostik und Therapie. Zeitschrift für Rheumatologie 65:4, 297-305
     CrossRef

211. 211

     Sophie Motte, Kathleen McEntee, Robert Naeije. (2006) Endothelin receptor antagonists. Pharmacology & Therapeutics 110:3, 386-414
     CrossRef

212. 212

     Michael H. Ieong, Harrison W. Farber. (2006) Noninfectious Pulmonary Complications of HIV. Clinical Pulmonary Medicine 13:3, 194-202
     CrossRef

213. 213

     Robyn J. Barst, David Langleben, David Badesch, Adaani Frost, E. Clinton Lawrence, Shelley Shapiro, Robert Naeije, Nazzareno Galie. (2006) Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Journal of the American College of Cardiology 47:10, 2049-2056
     CrossRef

214. 214

     Chao Liu, Kunshen Liu, Zhenguo Ji, Gang Liu. (2006) Treatments for pulmonary arterial hypertension. Respiratory Medicine 100:5, 765-774
     CrossRef

215. 215

     D. S. O'Callaghan, S. P. Gaine. (2006) Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. International Journal of Clinical Practice 60:4, 475-481
     CrossRef

216. 216

     Catherine M. Simpson, Daniel J. Penny, Andrew D. Cochrane, Andrew M. Davis, Michelle L. Rose, Sarah E. Wilson, Robert G. Weintraub. (2006) Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 25:4, 469-473
     CrossRef

217. 217

     Maria Szilasi, Tamás Dolinay, Zoltán Nemes, János Strausz. (2006) Pathology of chronic obstructive pulmonary disease. Pathology & Oncology Research 12:1, 52-60
     CrossRef

218. 218

     Carsten Höltke, Marilyn P. Law, Stefan Wagner, Hans-Jörg Breyholz, Klaus Kopka, Christoph Bremer, Bodo Levkau, Otmar Schober, Michael Schäfers. (2006) Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ETA receptor radioligands. Bioorganic & Medicinal Chemistry 14:6, 1910-1917
     CrossRef

219. 219

     Sonja D Bartolome, Richard N Channick. (2006) Sildenafil for pulmonary arterial hypertension. Future Cardiology 2:2, 137-143
     CrossRef

220. 220

     Michael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, Dirk Heimbach, Thomas Krahn, Christian Schröder, Stephan Siegel, Johannes-Peter Stasch, Hideki Tsujishita, Stefan Weigand, Nagahiro H. Yoshida. (2006) Selective Indole-Based ECE Inhibitors: Synthesis and Pharmacological Evaluation. ChemMedChem 1:1, 96-105
     CrossRef

221. 221

     Jennifer L. Snow, Peter Lloyd Jones, Darren B. Taichman. 2006. Pathobiologic Mechanisms of Pulmonary Arterial Hypertension. , 33-49.
     CrossRef

222. 222

     Erika Berman Rosenzweig, Robyn J Barst. (2006) Pulmonary Arterial Hypertension. Treatments in Respiratory Medicine 5:2, 117-127
     CrossRef

223. 223

     Herre J Reesink, Ronald C Meijer, René Lutter, Frans Boomsma, Henk M Jansen, Jaap J Kloek, Paul Bresser. (2006) Hemodynamic and Clinical Correlates of Endothelin-1 in Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal 70:8, 1058-1063
     CrossRef

224. 224

     Anna M. Hackman, Thomas E. Lackner. (2006) Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years. Pharmacotherapy 26:1, 68-94
     CrossRef

225. 225

     Kang Hyeon Choe. (2006) Complications of Chronic Obstructive Pulmonary Disease. Journal of the Korean Medical Association 49:4, 321
     CrossRef

226. 226

     Hideki Tsurugaya, Hitoshi Adachi, Masahiko Kurabayashi, Shigeru Ohshima, Koichi Taniguchi. (2006) Prognostic Impact of Ventilatory Efficiency in Heart Disease Patients With Preserved Exercise Tolerance. Circulation Journal 70:10, 1332-1336
     CrossRef

227. 227

     Emilio Mazza, Darren B. Taichman. 2006. Functions and Control of the Pulmonary Circulation. , 1-19.
     CrossRef

228. 228

     Noriyuki Homma, Yoshiteru Morio, Hideki Takahashi, Akihito Yamamoto, Tsutomu Suzuki, Koichi Sato, Masashi Muramatsu, Yoshinosuke Fukuchi. (2006) Genistein, a Phytoestrogen, Attenuates Monocrotaline-Induced Pulmonary Hypertension. Respiration 73:1, 105-112
     CrossRef

229. 229

     Kelly M. Chin, Peter F. Fedullo. 2006. Chronic Thromboembolic Pulmonary Hypertension. , 188-209.
     CrossRef

230. 230

     Jess Mandel. 2006. Treatment for Pulmonary Arterial Hypertension. , 99-118.
     CrossRef

231. 231

     Azad Raiesdana, Joseph Loscalzo. (2006) Pulmonary arterial hypertension. Annals of Medicine 38:2, 95-110
     CrossRef

232. 232

     Kevin B. MARTIN, James R. KLINGER, Sharon I. S. ROUNDS. (2006) Pulmonary arterial hypertension: New insights and new hope. Respirology 11:1, 6-17
     CrossRef

233. 233

     RALF GEIGER, WERNER PAJK, NIKOLAUS NEU, STEPHAN MAIER, AXEL KLEINSASSER, SOHRAB FRATZ, SALVADOR NAVARRO-PSIHA, VIKTORIA FISCHER, BENEDIKT TREML, ALEXANDER LOECKINGER. (2006) Tezosentan Decreases Pulmonary Artery Pressure and Improves Survival Rate in an Animal Model of Meconium Aspiration. Pediatric Research 59:1, 147-150
     CrossRef

234. 234

     Tian-Tai Zhang, Bing Cui, De-Zai Dai, Xiao-Yun Tang. (2005) Pharmacological Efficacy of CPU 86017 on Hypoxic Pulmonary Hypertension in Rats. Journal of Cardiovascular Pharmacology 46:6, 727-734
     CrossRef

235. 235

     Christophe Guilluy, Vincent Sauzeau, Malvyne Rolli-Derkinderen, Patrice Guérin, Christine Sagan, Pierre Pacaud, Gervaise Loirand. (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. British Journal of Pharmacology 146:7, 1010-1018
     CrossRef

236. 236

     Marc Humbert, Gérald Simonneau. (2005) Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nature Clinical Practice Rheumatology 1:2, 93-101
     CrossRef

237. 237

     Frank Langer, Michael Bauer, Dietmar Tscholl, Rene Schramm, Takashi Kunihara, Henning Lausberg, Thomas Georg, Heinrike Wilkens, Hans-Joachim Schäfers. (2005) Circulating big endothelin-1: An active role in pulmonary thromboendarterectomy?. The Journal of Thoracic and Cardiovascular Surgery 130:5, 1342-1347
     CrossRef

238. 238

     Mark L. Barr, Steven M. Kawut, Timothy P. Whelan, Reda Girgis, Heidi Böttcher, Joshua Sonett, Wickii Vigneswaran, David M. Follette, Paul A. Corris. (2005) Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part IV: Recipient-Related Risk Factors and Markers. The Journal of Heart and Lung Transplantation 24:10, 1468-1482
     CrossRef

239. 239

     Minoru Hongo, Eiichiro Mawatari, Akio Sakai, Zonghai Ruan, Tomonobu Koizumi, Fumiko Terasawa, Yoshikazu Yazaki, Osamu Kinoshita, Uichi Ikeda, Toshishige Shibamoto. (2005) Effects of Nicorandil on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Journal of Cardiovascular Pharmacology 46:4, 452-458
     CrossRef

240. 240

     Jason M. Aliotta, Michael Passero, Joseph Meharg, James Klinger, Mark S. Dooner, Jeffrey Pimentel, Peter J. Quesenberry. (2005) Stem cells and pulmonary metamorphosis: New concepts in repair and regeneration. Journal of Cellular Physiology 204:3, 725-741
     CrossRef

241. 241

     Georgette D. Kanmogne, Charles Primeaux, Paula Grammas. (2005) Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochemical and Biophysical Research Communications 333:4, 1107-1115
     CrossRef

242. 242

     Erika Berman Rosenzweig, D. Dunbar Ivy, Allison Widlitz, Aimee Doran, Lori R. Claussen, Delphine Yung, Steven H. Abman, Adele Morganti, Ngoc Nguyen, Robyn J. Barst. (2005) Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 46:4, 697-704
     CrossRef

243. 243

     Nazzareno Galié, David Badesch, Ronald Oudiz, Gérald Simonneau, Michael D. McGoon, Anne M. Keogh, Adaani E. Frost, Diane Zwicke, Robert Naeije, Shelley Shapiro, Horst Olschewski, Lewis J. Rubin. (2005) Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 46:3, 529-535
     CrossRef

244. 244

     J.C. Caraballo Fonseca, C.D. Martínez Balzano, R. Sánchez de León. (2005) Disfunción endotelial en la hipertensión pulmonar. Archivos de Bronconeumología 41:7, 389-392
     CrossRef

245. 245

     Lewis J Rubin, Christopher Dufton, Michael J Gerber. (2005) Ambrisentan for pulmonary arterial hypertension. Future Cardiology 1:4, 425-432
     CrossRef

246. 246

     Steeve Provencher, Olivier Sitbon, Gérald Simonneau. (2005) Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opinion on Pharmacotherapy 6:8, 1337-1348
     CrossRef

247. 247

     F. Nakhoul. (2005) The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrology Dialysis Transplantation 20:8, 1686-1692
     CrossRef

248. 248

     Hironori Yuyama, Akira Fujimori, Masanao Sanagi, Akiko Koakutsu, Yukiko Noguchi, Katsumi Sudoh, Masao Sasamata, Keiji Miyata. (2005) A novel and selective endothelin ETA receptor antagonistYM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats. Vascular Pharmacology 43:1, 40-46
     CrossRef

249. 249

     Steeve Provencher, Xavier Jais, Olivier Sitbon. (2005) Bosentan therapy for pulmonary arterial hypertension. Future Cardiology 1:3, 299-309
     CrossRef

250. 250

     (2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. Revista Española de Cardiología 58:5, 523-566
     CrossRef

251. 251

     Georgette D Kanmogne. (2005) Noninfectious pulmonary complications of HIV/AIDS. Current Opinion in Pulmonary Medicine 11:3, 208-212
     CrossRef

252. 252

     MAURICE BEGHETTI, STEPHEN M. BLACK, JEFFREY R. FINEMAN. (2005) Endothelin-1 in Congenital Heart Disease. Pediatric Research 57:5 Part 2, 16R-20R
     CrossRef

253. 253

     Ivan M. Robbins, Jason D. Morrow, Brian W. Christman. (2005) Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radical Biology and Medicine 38:5, 568-574
     CrossRef

254. 254

     Toko Shinkai, Hideki Shima, Valeria Solari, Prem Puri. (2005) Expression of vasoactive mediators during mechanical ventilation in nitrofen-induced diaphragmatic hernia in rats. Pediatric Surgery International 21:3, 143-147
     CrossRef

255. 255

     Gianluigi Giannelli, Florenzo Iannone, Felice Marinosci, Giovanni Lapadula, Salvatore Antonaci. (2005) The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Current Medical Research and Opinion 21:3, 327-332
     CrossRef

256. 256

     Darren B. Taichman, Harold I. Palevsky. (2005) Treatment of Pulmonary Arterial Hypertension With the Endothelin Receptor Antagonist Bosentan. Clinical Pulmonary Medicine 12:2, 121-127
     CrossRef

257. 257

     Roxana Sulica, Michael Poon. (2005) Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine. Expert Review of Cardiovascular Therapy 3:2, 347-360
     CrossRef

258. 258

     Pierre Beaucage, Marc Iglarz, Marc Servant, Rhian M Touyz, Pierre Moreau. (2005) Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis. Journal of Hypertension 23:2, 329-335
     CrossRef

259. 259

     C. Black. (2005) Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?. Rheumatology 44:2, 141-142
     CrossRef

260. 260

     Marius M Hoeper. (2005) Drug Treatment of Pulmonary Arterial Hypertension. Drugs 65:10, 1337-1354
     CrossRef

261. 261

     Shigetake Sasayama, Takeyoshi Kunieda, Hitonobu Tomoike, Masunori Matsuzaki, Kunio Shirato, Takayuki Kuriyama, Tohru Izumi, Hideki Origasa, Paul LM van Giersbergen, Jasper Dingemanse, Satoshi Tanaka. (2005) Effects of the Endothelin Receptor Antagonist Bosentan on Hemodynamics, Symptoms and Functional Capacity in Japanese Patients With Severe Pulmonary Hypertension. Circulation Journal 69:2, 131-137
     CrossRef

262. 262

     Michael Dandel, Hans B. Lehmkuhl, Roland Hetzer. (2005) Advances in the Medical Treatment of Pulmonary Hypertension. Kidney and Blood Pressure Research 28:5-6, 311-324
     CrossRef

263. 263

     Li L Yang, Sara Arab, Peter Liu, Duncan J Stewart, Mansoor Husain. (2005) The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Canadian Journal of Physiology and Pharmacology 83:1, 47-62
     CrossRef

264. 264

     Toshiro Katayama, Katsusuke Yano, Hiroshi Nakashima, Chisa Takagi, Yukiharu Honda, Shin Suzuki, Yoshihiro Iwasaki. (2005) Clinical Significance of Acute-Phase Endothelin-1 in Acute Myocardial Infarction Patients Treated With Direct Coronary Angioplasty. Circulation Journal 69:6, 654-658
     CrossRef

265. 265

     Robert K. Fitzgerald, Peter Oishi, Boaz Ovadia, Gregory A. Ross, Olaf Reinhartz, Michael J. Johengen, Jeffrey R. Fineman. (2004) Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension*. Pediatric Critical Care Medicine 5:6, 571-577
     CrossRef

266. 266

     Farber, Harrison W., Loscalzo, Joseph, . (2004) Pulmonary Arterial Hypertension. New England Journal of Medicine 351:16, 1655-1665
     Full Text

267. 267

     D. Montani, X. Jaïs, V. Ioos, O. Sitbon, G. Simonneau, M. Humbert. (2004) Traitement de l'hypertension artérielle pulmonaire. La Revue de Médecine Interne 25:10, 720-731
     CrossRef

268. 268

     Humbert, Marc, Sitbon, Olivier, Simonneau, Gérald, . (2004) Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 351:14, 1425-1436
     Full Text

269. 269

     Fraser D. Russell. (2004) Emerging roles of urotensin-II in cardiovascular disease. Pharmacology & Therapeutics 103:3, 223-243
     CrossRef

270. 270

     Irene M Lang, Diana Bonderman, Meinhard Kneussl, Manfred Marx. (2004) Paediatric pulmonary vascular disease. Paediatric Respiratory Reviews 5:3, 238-248
     CrossRef

271. 271

     Nicolas Bousette, Lisa Patel, Stephen A Douglas, Eliot H Ohlstein, Adel Giaid. (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176:1, 117-123
     CrossRef

272. 272

     Yolanda Braun-Moscovici, A.Menahem Nahir, Alexandra Balbir-Gurman. (2004) Endothelin and pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism 34:1, 442-453
     CrossRef

273. 273

     Hironori Yuyama, Akira Fujimori, Masanao Sanagi, Akiko Koakutsu, Katsumi Sudoh, Masao Sasamata, Keiji Miyata. (2004) The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. European Journal of Pharmacology 496:1-3, 129-139
     CrossRef

274. 274

     Erika Berman Rosenzweig, Allison C. Widlitz, Robyn J. Barst. (2004) Pulmonary arterial hypertension in children. Pediatric Pulmonology 38:1, 2-22
     CrossRef

275. 275

     Marc Humbert, Nicholas W Morrell, Stephen L Archer, Kurt R Stenmark, Margaret R MacLean, Irene M Lang, Brian W Christman, E.Kenneth Weir, Oliver Eickelberg, Norbert F Voelkel, Marlene Rabinovitch. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S13-S24
     CrossRef

276. 276

     Richard N Channick, Olivier Sitbon, Robyn J Barst, Alessandra Manes, Lewis J Rubin. (2004) Endothelin receptor antagonists in pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S62-S67
     CrossRef

277. 277

     Stephan Thelitz, Peter Oishi, Lucienne S. Sanchez, Janine M. Bekker, Boaz Ovadia, Michael J. Johengen, Stephen M. Black, Jeffrey R. Fineman. (2004) Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs*. Pediatric Critical Care Medicine 5:3, 234-239
     CrossRef

278. 278

     Marius M Hoeper, Michael J Krowka, Christian P Strassburg. (2004) Portopulmonary hypertension and hepatopulmonary syndrome. The Lancet 363:9419, 1461-1468
     CrossRef

279. 279

     Sheila A Doggrell. (2004) Endothelin-converting enzyme inhibitors and their potential for cardiovascular and renal therapeutics. Expert Opinion on Therapeutic Patents 14:5, 655-665
     CrossRef

280. 280

     Horst Olschewski, Frank Rose, Ralph Schermuly, H.Ardeschir Ghofrani, Beate Enke, Andrea Olschewski, Werner Seeger. (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 102:2, 139-153
     CrossRef

281. 281

     Vicki I. Jue. (2004) Phosphodiesterase Inhibitors in the Management of Primary Pulmonary Hypertension. Progress in Cardiovascular Nursing 19:2, 74-79
     CrossRef

282. 282

     Zen-Kong Dai, Mian-Shin Tan, Chee-Yin Chai, Jwu-Lai Yeh, Shah-Hwa Chou, Chaw-Chi Chiu, Arco Y. Jeng, Ing-Jun Chen, Jiunn-Ren Wu. (2004) Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatric Pulmonology 37:3, 249-256
     CrossRef

283. 283

     Kelly Chin, Richard Channick. (2004) Bosentan. Expert Review of Cardiovascular Therapy 2:2, 175-182
     CrossRef

284. 284

     Hanno H. Leuchte, Michael Holzapfel, Rainer A. Baumgartner, Isabelle Ding, Claus Neurohr, Michael Vogeser, Tilman Kolbe, Martin Schwaiblmair, Jürgen Behr. (2004) Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. Journal of the American College of Cardiology 43:5, 764-770
     CrossRef

285. 285

     Tim Higenbottam, Liz Laude, Celia Emery, Mohamed Essener. (2004) Pulmonary hypertension as a result of drug therapy. Clinics in Chest Medicine 25:1, 123-131
     CrossRef

286. 286

     Danny Chu, Christopher C Sullivan, Lingling Du, Augustine J Cho, Masakuni Kido, Paul L Wolf, Matthew D Weitzman, Stuart W Jamieson, Patricia A Thistlethwaite. (2004) A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. The Annals of Thoracic Surgery 77:2, 449-456
     CrossRef

287. 287

     Dermot O'Callaghan, Sean P. Gaine. (2004) Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. International Journal of Clinical Practice 58:1, 69-73
     CrossRef

288. 288

     Jean-Fran??ois Jasmin, Jocelyn Dupuis. (2004) Evaluation of Luminal Endothelin-Converting Enzyme Activity in the Pulmonary and Coronary Circulations. Journal of Cardiovascular Pharmacology 43:1, 21-25
     CrossRef

289. 289

     Carmine Savoia, Ernesto L Schiffrin. (2004) Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Medical Clinics of North America 88:1, 39-62
     CrossRef

290. 290

     Robert P. Jankov, A. Keith Tanswell. (2004) Growth factors, postnatal lung growth and bronchopulmonary dysplasia. Paediatric Respiratory Reviews 5, S265-S275
     CrossRef

291. 291

     Daphna Paran, Elizabeth Fireman, Ori Elkayam. (2004) Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmunity Reviews 3:1, 70-75
     CrossRef

292. 292

     Sohrab Fratz, Ralf Geiger, Hans Kresse, Gabriele Roemer, Michael Hennig, Walter Sebening, John Hess. (2003) Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1724-1729
     CrossRef

293. 293

     Gilbert Blaise, David Langleben, Bernard Hubert. (2003) Pulmonary Arterial Hypertension. Anesthesiology 99:6, 1415-1432
     CrossRef

294. 294

     Ioana R. Preston, Nicholas S. Hill. (2003) Evaluation and management of pulmonary hypertension in systemic sclerosis. Current Opinion in Rheumatology 15:6, 761-765
     CrossRef

295. 295

     M. Moreno de Sandino, A. Hernandez. (2003) Nitric Oxide Synthase Expression in the Endothelium of Pulmonary Arterioles in Normal and Pulmonary Hypertensive Chickens Subjected to Chronic Hypobaric Hypoxia. Avian Diseases 47:4, 1291-1297
     CrossRef

296. 296

     Mathieu Simon, Bruno Battistini, Yong Joo Kim, John Tsang. (2003) Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respiratory Physiology & Neurobiology 138:1, 97-106
     CrossRef

297. 297

     Hiroaki Arakawa, Eric J. Stern, Takaaki Nakamoto, Mutsuhisa Fujioka, Noboru Kaneko, Hiroshi Harasawa. (2003) Chronic Pulmonary Thromboembolism. Journal of Computer Assisted Tomography 27:5, 735-742
     CrossRef

298. 298

     Jeanette Strametz-Juranek, Richard Pacher, Thomas Kos, Wolfgang Woloszczuk, Michael Grimm, Andreas Zuckermann, Brigitte Stanek. (2003) Sequential big endothelin plasma levels in heart transplant recipients during bridging therapy and after successful heart transplantation. The Journal of Heart and Lung Transplantation 22:7, 731-737
     CrossRef

299. 299

     Georgia Trakada, Eugenia Nikolaou, Athanasia Pouli, Maria Tsiamita, Kostas Spiropoulos. (2003) Endothelin-1 Levels in Interstitial Lung Disease Patients During Sleep. Sleep and Breathing 7:3, 111-118
     CrossRef

300. 300

     S. Bhatia, J. F. Morrison, T. C. Bower, M. D. McGoon. (2003) Pulmonary Hypertension in the Setting of Acquired Systemic Arteriovenous Fistulas. Mayo Clinic Proceedings 78:7, 908-912
     CrossRef

301. 301

     Nicolas Bousette, Adel Giaid. (2003) Endothelin-1 in atherosclerosis and other vasculopathies. Canadian Journal of Physiology and Pharmacology 81:6, 578-587
     CrossRef

302. 302

     René P Michel, David Langleben, Jocelyn Dupuis. (2003) The endothelin system in pulmonary hypertension. Canadian Journal of Physiology and Pharmacology 81:6, 542-554
     CrossRef

303. 303

     James R Runo, James E Loyd. (2003) Primary pulmonary hypertension. The Lancet 361:9368, 1533-1544
     CrossRef

304. 304

     Ventzislav Petkov, Wilhelm Mosgoeller, Rolf Ziesche, Markus Raderer, Leopold Stiebellehner, Karin Vonbank, Georg-Christian Funk, Gerhard Hamilton, Clemens Novotny, Bernhard Burian, Lutz-Henning Block. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation 111:9, 1339-1346
     CrossRef

305. 305

     Maureen D. Mayes. (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis & Rheumatism 48:5, 1190-1199
     CrossRef

306. 306

     Rolf Ziesche. (2003) Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose. Wiener Klinische Wochenschrift 115:10, 351-365
     CrossRef

307. 307

     Udo Kaisers, Thilo Busch, Maria Deja, Bernd Donaubauer, Konrad J. Falke. (2003) Selective pulmonary vasodilation in acute respiratory distress syndrome. Critical Care Medicine 31:Supplement, S337-S342
     CrossRef

308. 308

     Kenneth W. Presberg, H. Erhan Dincer. (2003) Pathophysiology of pulmonary hypertension due to lung disease. Current Opinion in Pulmonary Medicine 9:2, 131-138
     CrossRef

309. 309

     Judy W. M. Cheng. (2003) Bosentan. Heart Disease 5:2, 161-169
     CrossRef

310. 310

     Alessandro Cosenzi. (2003) Enrasentan, an Antagonist of Endothelin Receptors. Cardiovascular Drug Reviews 21:1, 1-16
     CrossRef

311. 311

     A. E. M. BENAMOU, D. J. MARLIN, B. C. CALLINGHAM, R. C. HILEY, P. LEKEUX. (2003) Spasmogenic action of endothelin-1 on isolated equine pulmonary artery and bronchus. Equine Veterinary Journal 35:2, 190-196
     CrossRef

312. 312

     Peter J. Barnes. (2003) New Concepts in Chronic Obstructive Pulmonary Disease. Annual Review of Medicine 54:1, 113-129
     CrossRef

313. 313

     Adviye Ergul. (2003) Development of endothelin receptor antagonists as potential therapeutic agents. Expert Opinion on Therapeutic Patents 13:1, 33-44
     CrossRef

314. 314

     Sheila A Doggrell. (2002) The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opinion on Investigational Drugs 11:11, 1537-1552
     CrossRef

315. 315

     Myung H. Park, Robert L. Scott, Patricia A. Uber, Mandeep R. Mehra. (2002) Treatment of pulmonary hypertension: A promising new age. Catheterization and Cardiovascular Interventions 57:3, 395-403
     CrossRef

316. 316

     M COSSIO, Y MENON, W WILSON, B DEBOISBLANC. (2002) Life-threatening complications of systemic sclerosis. Critical Care Clinics 18:4, 819-839
     CrossRef

317. 317

     STUART LEHRMAN, PATRICIA ROMANO, WILLIAM FRISHMAN, AMBER RASHID, JAY DOBKIN, JOSEPH REICHEL. (2002) Primary Pulmonary Hypertension and Cor Pulmonale. Cardiology in Review 10:5, 265-278
     CrossRef

318. 318

     Barry H. Greenberg. (2002) Endothelin and Endothelin Receptor Antagonists in Heart Failure. Congestive Heart Failure 8:5, 257-261
     CrossRef

319. 319

     Sébastien Roux, Lewis J Rubin. (2002) Bosentan: a dual endothelin receptor antagonist. Expert Opinion on Investigational Drugs 11:7, 991-1002
     CrossRef

320. 320

     Ian Adatia. (2002) Recent advances in pulmonary vascular disease. Current Opinion in Pediatrics 14:3, 292-297
     CrossRef

321. 321

     RAFFAELLA SCORZA, MONICA CARONNI, SONIA BAZZI, FILIPPO NADOR, LORENZO BERETTA, RITA ANTONIOLI, LAURA ORIGGI, ALESSANDRA PONTI, MAURIZIO MARCHINI, MASSIMO VANOLI. (2002) Post-Menopause is the Main Risk Factor for Developing Isolated Pulmonary Hypertension in Systemic Sclerosis. Annals of the New York Academy of Sciences 966:1, 238-246
     CrossRef

322. 322

     Norbert F. Voelkel, Carlyne Cool, Laima Taraceviene-Stewart, Mark W. Geraci, Michael Yeager, Todd Bull, Michael Kasper, Rubin M. Tuder. (2002) Janus face of vascular endothelial growth factor: The obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Critical Care Medicine 30:Supplement, S251-S256
     CrossRef

323. 323

     Newman, John H., . (2002) Treatment of Primary Pulmonary Hypertension — The Next Generation. New England Journal of Medicine 346:12, 933-935
     Full Text

324. 324

     Rubin, Lewis J., Badesch, David B., Barst, Robyn J., Galiè, Nazzareno, Black, Carol M., Keogh, Anne, Pulido, Tomas, Frost, Adaani, Roux, Sébastien, Leconte, Isabelle, Landzberg, Michael, Simonneau, Gérald, . (2002) Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine 346:12, 896-903
     Full Text

325. 325

     Thomas Neunteufl, Rudolf Berger, Richard Pacher. (2002) Endothelin receptor antagonists in cardiology clinical trials. Expert Opinion on Investigational Drugs 11:3, 431-443
     CrossRef

326. 326

     Koh Ono, Akira Matsumori. (2002) Endothelin Antagonism with Bosentan: Current Status and Future Perspectives. Cardiovascular Drug Reviews 20:1, 1-18
     CrossRef

327. 327

     Wolfgang M. Kuebler, Hermann Kuppe. (2002) Capillary pressure-induced lung injury: fact or fiction?. Current Opinion in Anaesthesiology 15:1, 57-64
     CrossRef

328. 328

     Vallerie V McLaughlin. (2002) Medical management of primary pulmonary hypertension. Expert Opinion on Pharmacotherapy 3:2, 159-165
     CrossRef

329. 329

     O Sanchez, M Humbert, O Sitbon, H Nunes, G Garcia, G Simonneau. (2002) Hypertension artérielle pulmonaire associée aux connectivites. La Revue de Médecine Interne 23:1, 41-54
     CrossRef

330. 330

     Adviye Ergul. (2002) Endothelin-1 and Endothelin Receptor Antagonists as Potential Cardiovascular Therapeutic Agents. Pharmacotherapy 22:1, 54-65
     CrossRef

331. 331

     ADRIANO M. PELLICELLI, FABRIZIO PALMIERI, STEFANIA CICALINI, NICOLA PETROSILLO. (2001) Pathogenesis of HIV-Related Pulmonary Hypertension. Annals of the New York Academy of Sciences 946:1, 82-94
     CrossRef

332. 332

     Richard N Channick, Gérald Simonneau, Olivier Sitbon, Ivan M Robbins, Adaani Frost, Victor F Tapson, David B Badesch, Sébastien Roux, Maurizio Rainisio, Frédéric Bodin, Lewis J Rubin. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. The Lancet 358:9288, 1119-1123
     CrossRef

333. 333

     Trina K Jeffery, Janet C Wanstall. (2001) Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacology & Therapeutics 92:1, 1-20
     CrossRef

334. 334

     Andrew J. Maxwell, Nancy D. Bridges. (2001) Pediatric primary pulmonary hypertension. Current Treatment Options in Cardiovascular Medicine 3:5, 371-383
     CrossRef

335. 335

     Ralph Wiedemann, H.Ardeschir Ghofrani, Norbert Weissmann, Ralph Schermuly, Karin Quanz, Friedrich Grimminger, Werner Seeger, Horst Olschewski. (2001) Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. Journal of the American College of Cardiology 38:4, 1130-1136
     CrossRef

336. 336

     Nazzareno Galié, Alessandra Manes, Angelo Branzi. (2001) MEDICAL THERAPY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 529-537
     CrossRef

337. 337

     Rubin M. Tuder, Carlyne D. Cool, Michael Yeager, Laimute Taraseviciene-Stewart, Todd M. Bull, Norbert F. Voelkel. (2001) THE PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 405-418
     CrossRef

338. 338

     Barbara Meyrick. (2001) THE PATHOLOGY OF PULMONARY ARTERY HYPERTENSION. Clinics in Chest Medicine 22:3, 393-404
     CrossRef

339. 339

     Robyn J. Barst. (2001) MEDICAL THERPAY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 509-515
     CrossRef

340. 340

     Richard N. Channick, Lewis J. Rubin. (2001) NEW AND EXPERIMENTAL THERAPIES FOR PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 539-545
     CrossRef

341. 341

     Marlene Rabinovitch. (2001) PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine 22:3, 433-449
     CrossRef

342. 342

     Matthew J Shaw, Hani Shennib, Nicolas Bousette, Eliot H Ohlstein, Adel Giaid. (2001) Effect of endothelin receptor antagonist on lung allograft apoptosis and NOSII expression. The Annals of Thoracic Surgery 72:2, 386-390
     CrossRef

343. 343

     Ronald G Tilton, Tommy A Brock, Richard AF Dixon. (2001) Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Expert Opinion on Investigational Drugs 10:7, 1291-1308
     CrossRef

344. 344

     Sukhdeep Kaur, William H. Frishman, Inderpal Singh, Praveen Tamirisa, Anil Kumar. (2001) Endothelin as a Therapeutic Target in the Treatment of Cardiovascular Disease. Heart Disease 3:3, 176-188
     CrossRef

345. 345

     Erika Berman Rosenzweig, Robyn J Barst. (2001) Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 10:5, 811-823
     CrossRef

346. 346

     Lewis J. Rubin. (2001) Therapy of pulmonary hypertension: Targeting pathogenic mechanisms with selective treatment delivery. Critical Care Medicine 29:5, 1086-1087
     CrossRef

347. 347

     David B Badesch. 2001. Pulmonary Hypertension. .
     CrossRef

348. 348

     Rafal M Kedzierski, Masashi Yanagisawa. (2001) E NDOTHELIN S YSTEM : The Double-Edged Sword in Health and Disease. Annual Review of Pharmacology and Toxicology 41:1, 851-876
     CrossRef

349. 349

     Hiroshi Nakazawa, Masatoshi Hori, Takahisa Murata, Hiroshi Ozaki, Hideaki Karaki. (2001) Contribution of Chloride Channel Activation to the Elevated Muscular Tone of the Pulmonary Artery in Monocrotaline-Induced Pulmonary Hypertensive Rats. The Japanese Journal of Pharmacology 86:3, 310-315
     CrossRef

350. 350

     Lukas E. Spieker, Georg Noll, Thomas F. L??scher. (2001) Therapeutic Potential for Endothelin Receptor Antagonists in Cardiovascular Disorders. American Journal of Cardiovascular Drugs 1:4, 293-303
     CrossRef

351. 351

     Tine L.M. De Backer, Jan-Peter Smedema, St??phane G. Carlier. (2001) Current Management of Primary Pulmonary Hypertension. BioDrugs 15:12, 801-817
     CrossRef

352. 352

     Katsutoshi GOTO. (2001) Basic and Therapeutic Relevance of Endothelin-Mediated Regulation.. Biological & Pharmaceutical Bulletin 24:11, 1219-1230
     CrossRef

353. 353

     SD Lee, DS Lee, YG Chun, SH Paik, WS Kim, DS Kim, WD Kim, RM Tuder, NF Voelkel. (2000) Transforming Growth Factor-β1 Induces Endothelin-1 in a Bovine Pulmonary Artery Endothelial Cell Line and Rat Lungs via cAMP. Pulmonary Pharmacology & Therapeutics 13:6, 257-265
     CrossRef

354. 354

     A. Bush. (2000) Pulmonary hypertensive diseases. Paediatric Respiratory Reviews 1:4, 361-367
     CrossRef

355. 355

     Michael Wanecek, Eddie Weitzberg, Anders Rudehill, Anders Oldner. (2000) The endothelin system in septic and endotoxin shock. European Journal of Pharmacology 407:1-2, 1-15
     CrossRef

356. 356

     Abhijit Ray, Laxminarayan G Hegde, Anita Chugh, Jang B Gupta. (2000) Endothelin-receptor antagonists: current and future perspectives. Drug Discovery Today 5:10, 455-464
     CrossRef

357. 357

     Martin Fleisch, Gabor S??tsch, Xiao Wei Yan, Ren?? R. Wenzel, Christian Binggeli, Mario G. Bianchetti, Bernhard Meier, Wolfgang Kiowski, Thomas F. L??scher. (2000) Systemic, Pulmonary, and Renal Hemodynamic Effects of Endothelin ETA/B-Receptor Blockade in Patients with Maintained Left Ventricular Function. Journal of Cardiovascular Pharmacology 36:3, 302-309
     CrossRef

358. 358

     Aidan O'Brien, Sharon Rounds. (2000) Pulmonary hypertension update. Comprehensive Therapy 26:3, 190-196
     CrossRef

359. 359

     Robert P Jankov, Xiaoping Luo, Judy Cabacungan, Rosetta Belcastro, Helena Frndova, Stephen J Lye, A Keith Tanswell. (2000) Endothelin-1 and O2-Mediated Pulmonary Hypertension in Neonatal Rats: A Role for Products of Lipid Peroxidation. Pediatric Research 48:3, 289-298
     CrossRef

360. 360

     Don C. Rockey. (2000) Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: Implications for therapy. Gastroenterology 118:6, 1261-1265
     CrossRef

361. 361

     Ian Mullaney, Diane M Vaughan, Margaret R MacLean. (2000) Regional modulation of cyclic nucleotides by endothelin-1 in rat pulmonary arteries: direct activation of G _i 2-protein in the main pulmonary artery. British Journal of Pharmacology 129:5, 1042-1048
     CrossRef

362. 362

     Michael Boscoe, Andrew Goodwin, Mohamed Amrani, Magdi Yacoub. (2000) Endothelins and the lung. The International Journal of Biochemistry & Cell Biology 32:1, 41-62
     CrossRef

363. 363

     A. Makino, K. Kamata. (2000) Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats. Diabetes, Obesity and Metabolism 2:1, 47-55
     CrossRef

364. 364

     G. Inselmann, R. Jahns, A. J. Capell, P. Eigel, U. Nellessen, J. Ludwig. (2000) Rest and exercise hemodynamics before and after valve replacement-A combined doppler/catheter study. Clinical Cardiology 23:1, 32-38
     CrossRef

365. 365

     STEPHEN M. BLACK, JANINE M. BEKKER, MICHAEL J. JOHENGEN, ANDREW J. PARRY, SCOTT J. SOIFER, JEFFREY R. FINEMAN. (2000) Altered Regulation of the ET-1 Cascade in Lambs with Increased Pulmonary Blood Flow and Pulmonary Hypertension. Pediatric Research 47:1, 97
     CrossRef

366. 366

     Marlene Rabinovitch. (1999) Pulmonary hypertension: pathophysiology as a basis for clinical decision making. The Journal of Heart and Lung Transplantation 18:11, 1041-1053
     CrossRef

367. 367

     Robin H. Steinhorn, Jeffrey R. Fineman. (1999) The Pathophysiology of Pulmonary Hypertension in Congenital Heart Disease. Artificial Organs 23:11, 970-974
     CrossRef

368. 368

     Roland Wensel, Christian F Opitz, Franz X Kleber. (1999) Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure. The Journal of Heart and Lung Transplantation 18:9, 877-883
     CrossRef

369. 369

     Carlyne D. Cool, J. Scott Stewart, Priya Werahera, Gary J. Miller, Randy L. Williams, Norbert F. Voelkel, Rubin M. Tuder. (1999) Three-Dimensional Reconstruction of Pulmonary Arteries in Plexiform Pulmonary Hypertension Using Cell-Specific Markers. The American Journal of Pathology 155:2, 411-419
     CrossRef

370. 370

     Hiroo Itoh, Ayumu Yokochi, Rikako Yamauchi-Kohno, Kazuo Maruyama. (1999) Effects of the endothelin ETA receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. European Journal of Pharmacology 376:3, 233-238
     CrossRef

371. 371

     Richard D Jones, Janet C Wanstall, Agatha Gambino, Alyn H Morice. (1999) The effect of the endothelin ETA receptor antagonist CI-1020 on hypoxic pulmonary vasoconstriction. European Journal of Pharmacology 374:3, 367-375
     CrossRef

372. 372

     A Mark Evans, Hannah J Cobban, Graeme F Nixon. (1999) ET _A receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: a tyrosine kinase independent pathway. British Journal of Pharmacology 127:1, 153-160
     CrossRef

373. 373

     Jens Lutz, Matthias Gorenflo, Matthias Habighorst, Martin Vogel, Peter E. Lange, Berthold Hocher. (1999) Endothelin-1- and Endothelin-Receptors in Lung Biopsies of Patients with Pulmonary Hypertension due to Congenital Heart Disease. Clinical Chemistry and Laboratory Medicine 37:4, 423-428
     CrossRef

374. 374

     M. A. Pate, A. H. Chester, D. S. T. Crabbe, M. Amrani, T. J. Brown, A. G. Roach, M. H. Yacoub. (1999) Characterisation of Constrictor Endothelin Receptors in the Human Internal Thoracic Artery and Saphenous Vein. Journal of Cardiovascular Pharmacology 33:4, 567-572
     CrossRef

375. 375

     Takashi Miyauchi, Tomoh Masaki. (1999) PATHOPHYSIOLOGY OF ENDOTHELIN IN THE CARDIOVASCULAR SYSTEM. Annual Review of Physiology 61:1, 391-415
     CrossRef

376. 376

     Tatsuya Sasaki, Teruo Noguchi, Kazuo Komamura, Toshio Nishikimi, Hidetoshi Yoshikawa, Kunio Miyatake. (1999) Differential roles of endothelin-1 in the development of secondary pulmonary hypertension in patients with left heart failure with or without acute exacerbation. Journal of Cardiac Failure 5:1, 38-45
     CrossRef

377. 377

     Lewis J. Rubin. (1999) Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatric Pulmonology 27:S18, 194-197
     CrossRef

378. 378

     Janet J Maguire, Anthony P Davenport. (1999) The therapeutic potential of PD156707 and related butenolide endothelin antagonists. Expert Opinion on Investigational Drugs 8:1, 71-78
     CrossRef

379. 379

     Karina Lewis, Alain Cadieux, Giles A Rae, Jean-Philippe Gratton, Pedro D'Orléans-Juste. (1999) Nitric oxide limits the eicosanoid-dependent bronchoconstriction and hypotension induced by endothelin-1 in the guinea-pig. British Journal of Pharmacology 126:1, 93-102
     CrossRef

380. 380

     Ariela Benigni, Giuseppe Remuzzi. (1999) Endothelin antagonists. The Lancet 353:9147, 133-138
     CrossRef

381. 381

     R Owe-Young, C G Schyvens, R A Qasabian, A D Conigrave, P S Macdonald, D J Williamson. (1999) Transcriptional down-regulation of the rabbit pulmonary artery endothelin B receptor during phenotypic modulation. British Journal of Pharmacology 126:1, 103-110
     CrossRef

382. 382

     Tim Higenbottam, Kurt Stenmark, Gerald Simonneau. (1999) Treatments for severe pulmonary hypertension. The Lancet 353:9150, 338-340
     CrossRef

383. 383

     STEPHEN M. BLACK, MICHAEL J. JOHENGEN, SCOTT J. SOIFER. (1998) Coordinated Regulation of Genes of the Nitric Oxide and Endothelin Pathways during the Development of Pulmonary Hypertension in Fetal Lambs. Pediatric Research 44:6, 821-830
     CrossRef

384. 384

     Konstantin Alexiou, Thomas Dschietzig, Oliver Simsch, Michael Laule, Johannes Hundertmark, Gert Baumann, Karl Stangl. (1998) Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin. Journal of the American College of Cardiology 32:6, 1773-1778
     CrossRef

385. 385

     J. Leppert, Å. Ringqvist, B. E. Karlberg, I. Ringqvist. (1998) Whole-body cooling increases plasma endothelin-1 levels in women with primary 's phenomenon. Clinical Physiology 18:5, 420-425
     CrossRef

386. 386

     Hani Shennib, Jin Q. Kuang, Eliot H. Ohlstein, Adel Giaid. (1998) ENDOTHELIN RECEPTOR ANTAGONIST IMPROVES PULMONARY HEMODYNAMICS DURING LUNG ISCHEMIA/REPERFUSION INJURY1. Transplantation 66:7, 917-920
     CrossRef

387. 387

     Sean P Gaine, Lewis J Rubin. (1998) Primary pulmonary hypertension. The Lancet 352:9129, 719-725
     CrossRef

388. 388

     William G. Haynes, David J. Webb. (1998) Endothelin as a regulator of cardiovascular function in health and disease. Journal of Hypertension 16:8, 1081-1098
     CrossRef

389. 389

     Nicola A. Mason, David R. Springall, Margaret Burke, Jennifer Pollock, Ghada Mikhail, Magdi H. Yacoub, Julia M. Polak. (1998) High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. The Journal of Pathology 185:3, 313-318
     CrossRef

390. 390

     F. Perfetto, R. Tarquini, L. Tapparini, B. Tarquini. (1998) Influence of Non–Insulin-Dependent Diabetes Mellitus on Plasma Endothelin-1 Levels in Patients With Advanced Atherosclerosis. Journal of Diabetes and its Complications 12:4, 187-192
     CrossRef

391. 391

     Takashi Takahashi, Tsugiyasu Kanda, Masahiro Inoue, Hiroyuki Sumino, Isao Kobayashi, Aikichi Iwamoto, Ryozo Nagai. (1998) Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sciences 63:10, 137-143
     CrossRef

392. 392

     Volker Breu, Sylvie I Ertel, Sébastien Roux, Martine Clozel. (1998) The pharmacology of bosentan. Expert Opinion on Investigational Drugs 7:7, 1173-1192
     CrossRef

393. 393

     T Mikkola. (1998) Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. European Journal of Obstetrics & Gynecology and Reproductive Biology 79:1, 75-82
     CrossRef

394. 394

     Andrew C. G. Uprichard, Alan L. Metz, Hussein Hallak, Stephen J. Haleen. (1998) PD-156707: A Selective Endothelin-A Receptor Antagonist. Cardiovascular Drug Reviews 16:2, 89-104
     CrossRef

395. 395

     J. Schmeck, T. Koch, A. Heller, K. Ackern, B. Patt, H. Neuhof. (1998) The role of endothelin-1 as a mediator of the pressure response after air embolism in blood perfused lungs. Intensive Care Medicine 24:6, 605-611
     CrossRef

396. 396

     Graham P Love, Alan K Keenan. (1998) Cytotoxicity-Associated Effects of Reactive Oxygen Species on Endothelin-1 Secretion by Pulmonary Endothelial Cells. Free Radical Biology and Medicine 24:9, 1437-1445
     CrossRef

397. 397

     D.Dunbar Ivy, John P. Kinsella, James W. Ziegler, Steven H. Abman. (1998) Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. The Journal of Thoracic and Cardiovascular Surgery 115:4, 875-882
     CrossRef

398. 398

     Jocelyn Dupuis, Peter Cernacek, Jean-Claude Tardif, Duncan J. Stewart, Gilbert Gosselin, Ihor Dyrda, Raoul Bonan, Jacques Crépeau. (1998) Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. American Heart Journal 135:4, 614-620
     CrossRef

399. 399

     Christopher P. Coppola, Macy Au-Fliegner, John R. Gosche. (1998) Endothelin-1 Pulmonary Vasoconstriction in Rats with Diaphragmatic Hernia. Journal of Surgical Research 76:1, 74-78
     CrossRef

400. 400

     H Soukka, J Jalonen, P Kero, P Kääpä. (1998) Endothelin-1, atrial natriuretic peptide and pathophysiology of pulmonary hypertension in porcine meconium aspiration. Acta Paediatrica 87:4, 424-428
     CrossRef

401. 401

     Chandrashekhar R. Gandhi, Edwin M. Nemoto, Simon C. Watkins, Vladimir M. Subbotin. (1998) An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats. Liver 18:1, 39-48
     CrossRef

402. 402

     Jack Ferlinz. (1998) Right ventricular diastolic performance: Compliance characteristics with focus on pulmonary hypertension, right ventricular hypertrophy, and calcium channel blockade. Catheterization and Cardiovascular Diagnosis 43:2, 206-243
     CrossRef

403. 403

     Katrina Huntington, Pierre Picard, Gordon Moe, Duncan J. Stewart, Ana Albernaz, Juan Carlos Monge. (1998) Increased Cardiac and Pulmonary Endothelin-1 mRNA Expression in Canine Pacing-Induced Heart Failure. Journal of Cardiovascular Pharmacology 31, S424-S426
     CrossRef

404. 404

     H Soukka, J Jalonen, P Kero, P Ka¨a¨p. (1998) Endothelin-1, atrial natriuretic peptide and pathophysiology of pulmonary hypertension in porcine meconium aspiration. Acta Paediatrica 87:4, 424
     CrossRef

405. 405

     Mitsumasa Fukuchi, Adel Giaid. (1998) Expression of Endothelin-1 and Endothelin-Converting Enzyme-1 mRNAs and Proteins in Failing Human Hearts. Journal of Cardiovascular Pharmacology 31, S421-S423
     CrossRef

406. 406

     Tatsuya Sasaki, Shigehiro Tomimoto, Teruo Noguchi, Takeshi Baba, Kazuo Komamura, Fumio Ohmori, Kunio Miyatake. (1998) Hemodynamic Effect of Amrinone Depends on Pretreatment Vascular Resistance in Patients with Evolving Congestive Heart Failure: Correlation Between Vascular Resistance and Neurohormonal Activity. Journal of Cardiovascular Pharmacology 31:1, 80-84
     CrossRef

407. 407

     David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Calvert S. Louden, Timothy K. Hart, Eliot H. Ohlstein, Douglas W. P. Hay. (1998) Chronic Hypoxia-Induced Cardiopulmonary Changes in Three Rat Strains: Inhibition by the Endothelin Receptor Antagonist SB 217242. Journal of Cardiovascular Pharmacology 31, S453-S455
     CrossRef

408. 408

     Shin-ichi Takeda, Shinichiro Miyoshi, Ken-ichi Omori, Tomoki Utsumi, Shigetoyo Kogaki, Yoshiki Sawa, Masashi Yanagisawa, Hikaru Matsuda. (1998) Pulmonary Disease Models Induced by In Vivo Hemagglutinating Virus of Japan Liposome-Mediated Endothelin-1 Gene Transfer. Journal of Cardiovascular Pharmacology 31, S336-S338
     CrossRef

409. 409

     Ian Mullaney, Diane M. Vaughan, Margaret M. MacLean. (1998) Endothelin-1 Modulation of cAMP in Rat Pulmonary Arteries: Effect of Chronic Hypoxia. Journal of Cardiovascular Pharmacology 31, S112-S114
     CrossRef

410. 410

     T Nagase, T Aoki, H Matsui, E Ohga, Hiroyuki Katayama, S Teramoto, T Matsuse, Y Fukuchi, Y Ouchi. (1997) Airway and lung tissue behaviour during endothelin-1 induced constriction in rats: effects of receptor antagonists. Canadian Journal of Physiology and Pharmacology 75:12, 1369-1374
     CrossRef

411. 411

     Scott B. Kribbs, Mark J. Clair, R.Stephen Krombach, Jennifer W. Hendrick, Patrick B. Thomas, Anthony T. Keever, Ward V. Houck, Rupak Mukherjee, Francis G. Spinale. (1997) Pulmonary hemodynamics and endothelin levels in pacing-induced heart failure: During rest and exercise. Journal of Cardiac Failure 3:4, 263-270
     CrossRef

412. 412

     K. R. Stenmark, R. P. Mecham. (1997) CELLULAR AND MOLECULAR MECHANISMS OF PULMONARY VASCULAR REMODELING. Annual Review of Physiology 59:1, 89-144
     CrossRef

413. 413

     Mark, Eugene J., Patalas, Eva D., Chang, Howard T., Evans, Richard J., Kessler, Stanton C., . (1997) Fatal Pulmonary Hypertension Associated with Short-Term Use of Fenfluramine and Phentermine. New England Journal of Medicine 337:9, 602-606
     Full Text

414. 414

     Mahmudul Hassan, Hiromasa Kashimura, Kazuhiko Matsumaru, Akira Nakahara, Hisayuki Fukutomi, Hiroshi Muto, Katsutoshi Goto, Naomi Tanaka. (1997) Phosphoramidon, an endothelin converting enzyme inhibitor attenuates local gastric ischemia-reperfusion injury in rats. Life Sciences 61:10, PL141-PL147
     CrossRef

415. 415

     Francisco Pérez-Vizcaíno, Eduardo Villamor, Juan Duarte, Juan Tamargo. (1997) Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A ₂ -mimetic U46619. British Journal of Pharmacology 121:7, 1323-1333
     CrossRef

416. 416

     Shi-Juan Chen, Yiu-Fai Chen, Terry J. Opgenorth, Jerry L. Wessale, Qing Cheng Meng, Joan Durand, Vick S. DiCarlo, Suzanne Oparil. (1997) The Orally Active Nonpeptide Endothelin A-Receptor Antagonist A-127722 Prevents and Reverses Hypoxia-Induced Pulmonary Hypertension and Pulmonary Vascular Remodeling in Sprague-Dawley Rats. Journal of Cardiovascular Pharmacology 29:6, 713-725
     CrossRef

417. 417

     Andrew A. Mortlock, Colin Bath, Roger J. Butlin, Christine Heys, Sarah J. Hunt, Alan C. Reid, Neil F. Sumner, Eric K. Tang, Elaine Whiting, Campbell Wilson, Nicola D. Wright. (1997) N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide; one of a class of novel benzenesulphonamides which are orally-active, ETA-selective endothelin antagonists. Bioorganic & Medicinal Chemistry Letters 7:11, 1399-1402
     CrossRef

418. 418

     Michael Wanecek, Anders Rudehill, Anette Hemsen, Jan M. Lundberg, Eddie Weitzberg. (1997) The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Critical Care Medicine 25:5, 848-857
     CrossRef

419. 419

     Stephen J Haleen, Xue-Min Cheng. (1997) Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. Expert Opinion on Investigational Drugs 6:5, 475-487
     CrossRef

420. 420

     P.C. Mills, A.J. Higgins. (1997) Oxidant injury, nitric oxide and pulmonary vascularfunction: Implications for the exercising horse. The Veterinary Journal 153:2, 125-148
     CrossRef

421. 421

     David B. Badesch, MD. (1997) CLINICAL TRIALS IN PULMONARY HYPERTENSION. Annual Review of Medicine 48:1, 399-408
     CrossRef

422. 422

     Rubin, Lewis J., . (1997) Primary Pulmonary Hypertension. New England Journal of Medicine 336:2, 111-117
     Full Text

423. 423

     Cyril Serrick, MSc, Adel Giaid, PhD, Alex Reis, MD, Hani Shennib, MD. (1997) Prolonged Ischemia Is Associated With More Pronounced Rejection in the Lung Allograft. The Annals of Thoracic Surgery 63:1, 202-208
     CrossRef

424. 424

     R. L. Patrick Rhoten, Youssef G. Comair, Daniel Shedid, Douglas Chyatte, Michael S. Simonson. (1997) Specific repression of the preproendothelin-1 gene in intracranial arteriovenous malformations. Journal of Neurosurgery 86:1, 101-108
     CrossRef

425. 425

     Maria L. Webb, Thomas D. Meek. (1997) Inhibitors of endothelin. Medicinal Research Reviews 17:1, 17-67
     CrossRef

426. 426

     Gabor Stsch, Osmund Bertel, Wolfgang Kiowski. (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovascular Drugs and Therapy 10:6, 717-725
     CrossRef

427. 427

     Satoshi Sakai, Takashi Miyauchi, Takeshi Sakurai, Iwao Yamaguchi, Masahiko Kobayashi, Katsutoshi Goto, Yasuro Sugishita. (1996) Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. Journal of the American College of Cardiology 28:6, 1580-1588
     CrossRef

428. 428

     Chandrashekhar R. Gandhi, Yoogoo Kang, Andre De Wolf, Juan Madariaga, Shushma Aggarwal, Victor Scott, John Fung. (1996) Altered endothelin homeostasis in patients undergoing liver transplantation. Liver Transplantation and Surgery 2:5, 362-369
     CrossRef

429. 429

     David Hasdai, Eldad Erez, Irit Gil-Ad, Ehud Raanani, Samuel Sclarovsky, Yaakov Barak, Jaqueline Sulkes, Bernardo A. Vidne. (1996) Is the heart a source for elevated circulating endothelin levels during aorta—coronary artery bypass grafting surgery in human beings?. The Journal of Thoracic and Cardiovascular Surgery 112:2, 531-536
     CrossRef

430. 430

     Raul Altman, Aleiandra Scazziota, Jorge Rouvier, Enrique Gurfinkei, Roberto Favaloro, Sergio Perrone, Jawed Fareed. (1996) Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clinical Cardiology 19:7, 549-554
     CrossRef

431. 431

     L. L. Wallman, R. Penny, D. J. Williamson. (1996) Pulmonary vascular aspects of systemic sclerosis. Australian and New Zealand Journal of Medicine 26:2, 150-153
     CrossRef

432. 432

     Paul C. Kuo. (1996) Pulmonary hypertension: considerations in the liver transplant candidate. Transplant International 9:2, 141-150
     CrossRef

433. 433

     D. DUNBAR IVY, JAMES W. ZIEGLER, MARY F. DUBUS, JONATHAN J. FOX, JOHN P. KINSELLA, STEVEN H. ABMAN. (1996) Chronic Intrauterine Pulmonary Hypertension Alters Endothelin Receptor Activity in the Ovine Fetal Lung. Pediatric Research 39:3, 435-442
     CrossRef

434. 434

     Helmut Drexler, M.D, Andrew J.S. Coats, M.D. (1996) EXPLAINING FATIGUE IN CONGESTIVE HEART FAILURE. Annual Review of Medicine 47:1, 241-256
     CrossRef

435. 435

     Annette M. Doherty. (1996) Design and discovery of nonpeptide endothelin antagonists. Drug Discovery Today 1:2, 60-70
     CrossRef

436. 436

     J Lie. (1995) Plexogenic pulmonary hypertension associated with intravenous cocaine abuse. Cardiovascular Pathology 4:4, 235-238
     CrossRef

437. 437

     W Kiowski, J Kim, E Oechslin, G Sütsch, P Hunziker, P Müller, O Bertel, R Schmitt, R Jones. (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. The Lancet 346:8977, 732-736
     CrossRef

438. 438

     Epstein, Franklin H., , Levin, Ellis Robert, . (1995) Endothelins. New England Journal of Medicine 333:6, 356-363
     Full Text

439. 439

     Annette Kent, Alan K. Keenan. (1995) Evidence for signalling by big endothelin-1 via conversion to endothelin-1 in pulmonary artery smooth muscle cells. Life Sciences 57:12, 1191-1196
     CrossRef

440. 440

     Loscalzo, Joseph, . (1995) Nitric Oxide and Vascular Disease. New England Journal of Medicine 333:4, 251-253
     Full Text

441. 441

     Giaid, Adel, Saleh, Dina, . (1995) Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine 333:4, 214-221
     Full Text

442. 442

     Shiro Ishikawa, Takashi Miyauchi, Satoshi Sakai, Hiroya Ushinohama, Kouichi Sagawa, Naoki Fusazaki, Hideaki Kado, Hiroshi Sunagawa, Sonao Honda, Hayao Ueno, Iwao Yamaguchi, Yasuro Sugishita, Katsutoshi Goto. (1995) Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. The Journal of Thoracic and Cardiovascular Surgery 110:1, 271-273
     CrossRef

443. 443

     Danny Ling Wang, Being-Sun Wung, Yi-Ching Peng, Jaang Jung Wang. (1995) Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells. Journal of Cellular Physiology 163:2, 400-406
     CrossRef

444. 444

     Atsuhiro Kawashima, Akiko Kimura, Shogo Katsuda, Ryo Sumita, Akihiro Yachie, Akitaka Nonomura, Isao Nakanishi. (1995) Pulmonary vasculitis with hypereosinophilia and episodic pulmonary hypertension: Report of three siblings. Pathology International 45:1, 66-74
     CrossRef

445. 445

     Giles A. Rae, João B. Calixto, Pedro D'Orléans-Juste. (1995) Effects and mechanisms of action of endothelins on non-vascular smooth muscle of the respiratory, gastrointestinal and urogenital tracts. Regulatory Peptides 55:1, 1-46
     CrossRef

446. 446

     Kevin W. Buchan, Helgo Magnusson, Klaus F. Rabe, Michael J. Sumner, Ian S. Watts. (1994) Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005. European Journal of Pharmacology 260:2-3, 221-225
     CrossRef

447. 447

     Dong Xu, Noriaki Emoto, Adel Giaid, Clive Slaughter, Semiko Kaw, Damiane deWit, Masashi Yanagisawa. (1994) ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78:3, 473-485
     CrossRef

448. 448

     David Hasdai, Ran Kornowski, Alexander Battler. (1994) Endothelin and myocardial ischemia. Cardiovascular Drugs and Therapy 8:4, 589-599
     CrossRef

449. 449

     Timothy D. Warner. (1994) Endothelin Receptor Antagonists. Cardiovascular Drug Reviews 12:2, 105-122
     CrossRef

450. 450

     Epstein, Franklin H., , Gibbons, Gary H.Dzau, Victor J.. (1994) The Emerging Concept of Vascular Remodeling. New England Journal of Medicine 330:20, 1431-1438
     Full Text

451. 451

     Samuel N. Breit, Stephen C. Thornton, Ronald Penny. (1994) Lung involvement in Scleroderma. Clinics in Dermatology 12:2, 243-252
     CrossRef

452. 452

     Yasuhiro Hosoda. (1994) Pathology of pulmonary hypertension: A human and experimental study. Pathology International 44:4, 241-267
     CrossRef

453. 453

     (1993) Endothelin-1 in Pulmonary Hypertension. New England Journal of Medicine 329:26, 1967-1968
     Full Text

454. 454

     Lena M Macara, John CP Kingdom, Peter Kaufmann. (1993) Control of the fetoplacental circulation. Fetal and Maternal Medicine Review 5:03, 167
     CrossRef

Letters